<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Statins for women with polycystic ovary syndrome not actively trying to conceive - Xiong, T - 2023 | Cochrane Library</title> <meta content="Statins for women with polycystic ovary syndrome not actively trying to conceive - Xiong, T - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008565.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Statins for women with polycystic ovary syndrome not actively trying to conceive - Xiong, T - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008565.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008565.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Statins for women with polycystic ovary syndrome not actively trying to conceive" name="citation_title"/> <meta content="Ting Xiong" name="citation_author"/> <meta content="Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology" name="citation_author_institution"/> <meta content="txiong@tjh.tjmu.edu.cn" name="citation_author_email"/> <meta content="Eloise Fraison" name="citation_author"/> <meta content="Hôpital Femme Mère Enfant" name="citation_author_institution"/> <meta content="Eleni Kolibianaki" name="citation_author"/> <meta content="Aristotle University of Thessaloniki" name="citation_author_institution"/> <meta content="Michael F Costello" name="citation_author"/> <meta content="School of Clinical Medicine, UNSW and Royal Hospital for Women and Monash IVF" name="citation_author_institution"/> <meta content="Christos Venetis" name="citation_author"/> <meta content="UNSW Medicine" name="citation_author_institution"/> <meta content="Elena B Kostova" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD008565.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/07/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008565.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008565.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008565.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Acne Vulgaris [drug therapy]; Contraceptives, Oral [therapeutic use]; Hirsutism [drug therapy]; *Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use]; *Metformin [therapeutic use]; *Polycystic Ovary Syndrome [complications, drug therapy]; Testosterone [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008565.pub3&amp;doi=10.1002/14651858.CD008565.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008565\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008565\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","hr","fa","fr","pl","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008565.pub3",title:"Statins for women with polycystic ovary syndrome not actively trying to conceive",firstPublishedDate:"Jul 18, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008565.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008565.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008565.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008565.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008565.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008565.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008565.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008565.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008565.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008565.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1871 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008565.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-sec-0190"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-sec-0184"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/appendices#CD008565-sec-0195"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/supinfo/CD008565-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/supinfo/CD008565-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Statins for women with polycystic ovary syndrome not actively trying to conceive</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information#CD008565-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ting Xiong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information#CD008565-cr-0005">Eloise Fraison</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information#CD008565-cr-0006">Eleni Kolibianaki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information#CD008565-cr-0007">Michael F Costello</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information#CD008565-cr-0008">Christos Venetis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information#CD008565-cr-0009">Elena B Kostova</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information/en#CD008565-sec-0205">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 July 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008565.pub3">https://doi.org/10.1002/14651858.CD008565.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008565-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008565-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008565-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008565-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008565-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD008565-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008565-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008565-abs-0001" lang="en"> <section id="CD008565-sec-0001"> <h3 class="title" id="CD008565-sec-0001">Background</h3> <p>Statins are lipid‐lowering agents with pleiotropic actions. Experts have proposed that in addition to improving the dyslipidaemia associated with polycystic ovary syndrome (PCOS), statins may also exert other beneficial metabolic and endocrine effects, such as reducing testosterone levels. This is an update of a Cochrane Review first published in 2011. </p> </section> <section id="CD008565-sec-0002"> <h3 class="title" id="CD008565-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of statin therapy in women with PCOS who are not actively trying to conceive. </p> </section> <section id="CD008565-sec-0003"> <h3 class="title" id="CD008565-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecology and Fertility Group specialised register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHLs, and four ongoing trials registers on 7 November 2022. We also handsearched relevant conference proceedings and the reference lists of relevant trials for any additional studies, and we contacted experts in the field for any further ongoing studies. </p> </section> <section id="CD008565-sec-0004"> <h3 class="title" id="CD008565-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that evaluated the effects of statin therapy in women with PCOS not actively trying to conceive. Eligible comparisons were statin versus placebo or no treatment, statin plus another agent versus the other agent alone, and statin versus another agent. We performed statistical analysis using Review Manager 5, and we assessed the certainty of the evidence using GRADE methods. </p> </section> <section id="CD008565-sec-0005"> <h3 class="title" id="CD008565-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodology. Our primary outcomes were resumption of menstrual regularity and resumption of spontaneous ovulation. Our secondary outcomes were clinical and physiological measures including hirsutism, acne severity, testosterone levels, and adverse events. </p> </section> <section id="CD008565-sec-0006"> <h3 class="title" id="CD008565-sec-0006">Main results</h3> <p>Six RCTs fulfilled the criteria for inclusion. They included 396 women with PCOS who received six weeks, three months, or six months of treatment; 374 women completed the studies. Three studies evaluated the effects of simvastatin and three studies evaluated the effects of atorvastatin. We summarised the results of the studies under the following comparisons. </p> <p><b>Statins versus placebo (3 RCTs)</b> </p> <p>One trial measured resumption of menstrual regularity as menstrual cycle length in days. We are uncertain if statins compared with placebo shorten the mean length of the menstrual cycle (mean difference (MD) −2.00 days, 95% confidence interval (CI) −24.86 to 20.86; 37 participants; very low‐certainty evidence). No studies reported resumption of spontaneous ovulation, improvement in hirsutism, or improvement in acne. </p> <p>We are uncertain if statins compared with placebo reduce testosterone levels after six weeks (MD 0.06, 95% CI −0.72 to 0.84; 1 RCT, 20 participants; very low‐certainty evidence), after 3 months (MD −0.53, 95% CI −1.61 to 0.54; 2 RCTs, 64 participants; very low‐certainty evidence), or after 6 months (MD 0.10, 95% CI −0.43 to 0.63; 1 RCT, 28 participants; very low‐certainty evidence) </p> <p>Two studies recorded adverse events, and neither reported significant differences between the groups. </p> <p><b>Statins plus metformin versus metformin alone (1 RCT)</b> </p> <p>The single RCT included in this comparison measured resumption of menstrual regularity as the number of spontaneous menses per six months. We are uncertain if statins plus metformin compared with metformin improves resumption of menstrual regularity (MD 0.60 menses, 95% CI 0.08 to 1.12; 69 participants; very low‐certainty evidence). The study did not report resumption of spontaneous ovulation. </p> <p>We are uncertain if statins plus metformin compared with metformin alone improves hirsutism measured using the Ferriman‐Gallwey score (MD −0.16, 95% CI −0.91 to 0.59; 69 participants; very low‐certainty evidence), acne severity measured on a scale of 0 to 3 (MD −0.31, 95% CI −0.67 to 0.05; 69 participants; very low‐certainty evidence), or testosterone levels (MD −0.03, 95% CI −0.37 to 0.31; 69 participants; very low‐certainty evidence). The study reported that no significant adverse events occurred. </p> <p><b>Statins plus oral contraceptive pill versus oral contraceptive pill alone (1 RCT)</b> </p> <p>The single RCT included in this comparison did not report resumption of menstrual regularity or spontaneous ovulation. We are uncertain if statins plus the oral contraceptive pill (OCP) improves hirsutism compared with OCP alone (MD −0.12, 95% CI −0.41 to 0.17; 48 participants; very low‐certainty evidence). The study did not report improvement in acne severity. We are also uncertain if statins plus OCP compared with OCP alone reduces testosterone levels, because the certainty of the evidence was very low (MD −0.82, 95% CI −1.38 to −0.26; 48 participants). The study reported that no participants experienced significant side effects. </p> <p><b>Statins versus metformin (2 RCTs)</b> </p> <p>We are uncertain if statins improve menstrual regularity compared with metformin (number of spontaneous menses per six months) compared to metformin (MD 0.50 menses, 95% CI −0.05 to 1.05; 1 RCT, 61 participants, very low‐certainty evidence). No studies reported resumption of spontaneous ovulation. </p> <p>We are uncertain if statins compared with metformin reduce hirsutism measured using the Ferriman‐Gallwey score (MD −0.26, 95% CI −0.97 to 0.45; 1 RCT, 61 participants; very low‐certainty evidence), acne severity measured on a scale of 0 to 3 (MD −0.18, 95% CI −0.53 to 0.17; 1 RCT, 61 participants; very low‐certainty evidence), or testosterone levels (MD −0.24, 95% CI −0.58 to 0.10; 1 RCT, 61 participants; very low‐certainty evidence). </p> <p>Both trials reported that no significant adverse events had occurred.</p> <p><b>Statins versus oral contraceptive pill plus flutamide (1 RCT)</b> </p> <p>According to the study report, no participants experienced any significant side effects. There were no available data for any other main outcomes. </p> </section> <section id="CD008565-sec-0007"> <h3 class="title" id="CD008565-sec-0007">Authors' conclusions</h3> <p>The evidence for all main outcomes of this review was of very low certainty. Due to the limited evidence, we are uncertain if statins compared with placebo, or statins plus metformin compared with metformin alone, improve resumption of menstrual regularity. The trial evaluating statin plus OCP versus OCP alone reported neither of our primary outcomes. No other studies reported resumption of spontaneous ovulation. We are uncertain if statins improve hirsutism, acne severity, or testosterone. All trials that measured adverse events reported no significant differences between the groups. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008565-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008565-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008565-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008565-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008565-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008565-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008565-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008565-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/ro#CD008565-abs-0016">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008565-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD008565-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008565-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008565-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008565-abs-0002" lang="en"> <h3>What are the benefits and risks of statins for women with polycystic ovary syndrome who are not trying to get pregnant? </h3> <p><b>Key messages</b> <br/>1. We are uncertain if statins improve the regularity of menstrual periods, hirsutism (excessive hair growth), acne (pimples), or levels of testosterone (male sex hormone).<br/>2. No studies looked at spontaneous ovulation. <br/>3. Statins may not increase the risk of unwanted events, though the evidence is limited. </p> <p><b>What is polycystic ovary syndrome?</b> </p> <p>Women with polycystic ovary syndrome (PCOS) may suffer from irregular periods, hirsutism (excessive hair growth on body areas where hair typically grown on men, including the face, chest, and back), and acne (pimples) because of androgen excess (high levels of male hormones). This condition can affect women of any age, but is most common in those who have menstrual periods. </p> <p><b>How can polycystic ovary syndrome be treated?</b> </p> <p>Statins are medicines that help lower the levels of 'bad' lipids (fats) in the blood to prevent heart disease; they may also prevent other metabolic conditions. High levels of male hormones (testosterone) is one of the most prominent features of PCOS. This is called androgen excess, and it is associated with several metabolic disorders such as insulin resistance, diabetes, and increased risk of heart disease. Therefore, reducing the level of male hormones could be beneficial for women with PCOS. Statins may interfere with male hormone production, but it is unclear whether they can directly reduce testosterone levels. Long‐term use of statins may have risks. Therefore, it is important to evaluate the benefits and risks of statins in women with PCOS. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know whether any type of statin has benefits for women with PCOS who are not actively trying to get pregnant. We were interested in the effect of statins on: </p> <p>1. increasing the regularity of menstrual cycles and ovulation; and<br/>2. reducing hair excess, acne, and testosterone levels. </p> <p>We also wanted to know if statins have any unwanted effects. This is an update of a review first published in 2011. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that evaluated statins compared with placebo (dummy treatment), no treatment, or another medicine, in women with PCOS who were not trying to get pregnant. We were only interested in studies that allocated each woman to one or another treatment at random. This type of study usually provides the most reliable evidence about the effects of a treatment. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We included six studies that enrolled a total of 396 women. Four studies were conducted in Europe (265 women), one in the USA (20 women), and one in Iran (111 women). Pharmaceutical companies funded three studies. </p> <p><b>Main results</b> </p> <p>We are uncertain if statins compared with placebo, or statins plus metformin compared with metformin alone, improve the regularity of menstrual periods. No studies reported resumption of ovulation. We are uncertain if statins improve hirsutism, acne, or testosterone levels. All the studies that recorded unwanted effects found no clear differences in unwanted effects between the group of women taking statins and the other treatment group. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We included very few studies, most of which enrolled few women, and the results were very inconsistent across studies. For these reasons, we have very little confidence in the evidence. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is current up to 7 November 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008565-sec-0190" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008565-sec-0190"></div> <h3 class="title" id="CD008565-sec-0191">Implications for practice</h3> <section id="CD008565-sec-0191"> <p>The evidence for all main outcomes of this review was of very low certainty. Due to the limited evidence, we are uncertain if statins compared with placebo, or statins plus metformin compared with metformin alone, improve resumption of menstrual regularity in women with polycystic ovary syndrome (PCOS) not actively trying to conceive. The study comparing statins plus oral contraceptive pill (OCP) versus OCP alone reported neither of our primary outcomes. No studies reported resumption of spontaneous ovulation. We are uncertain if statins alone improve hirsutism, acne, or testosterone levels compared with placebo, metformin, or OCP. We are also uncertain if statins plus metformin versus metformin alone or statins plus OCP versus OCP alone improve hirsutism, acne, or testosterone levels. There were no reported differences in adverse effects between treatment groups. </p> </section> <h3 class="title" id="CD008565-sec-0192">Implications for research</h3> <section id="CD008565-sec-0192"> <p>Consumer‐related outcomes are of major concern in the field of gynaecology, which means studies must measure adverse events. Limited data were available on the efficacy of statins for improving resumption of menstrual regularity, hirsutism, or acne; and there were no data on resumption of spontaneous ovulation. There is a need for large studies with primary outcomes such as resumption of menstrual cycle and resumption of ovulation. It is important to report the time of administration of certain statins. Future studies should include large sample sizes and take precautions to minimise potential bias in outcome measurement. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008565-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008565-sec-0008"></div> <div class="table" id="CD008565-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Statin compared to placebo for women with polycystic ovary syndrome not actively trying to conceive</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Statin compared to placebo for women with polycystic ovary syndrome not actively trying to conceive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome not actively trying to conceive<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> statin<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with statin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Resumption of menstrual regularity</b> (menstrual cycle length in days) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual cycle length was 52 days.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2 days fewer<br/>(24.86 fewer to 20.86 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Resumption of spontaneous ovulation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No studies reported spontaneous ovulation.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Improvement in hirsutism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No studies reported hirsutism.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Improvement in acne severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No studies reported acne severity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Improvement in testosterone level</b> (nmol/L) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 6 weeks' treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level after 6 weeks' treatment was −0.58 nmol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 nmol/L higher<br/>(0.72 lower to 0.84 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 3 months' treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level (nmol/L) after 3 months' treatment was −0.1 nmol/L. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.53 nmol/L lower<br/>(1.61 lower to 0.54 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 6 months' treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level (nmol/L) after 6 months' treatment was −0.2 nmol/L. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.10 nmol/L higher<br/>(0.43 lower to 0.63 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>2 studies assessed adverse events and neither reported a significant difference between the groups.<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision (wide CI, small sample size) and once for risk of bias.<br/><sup>b</sup> One woman in the statin group stopped the treatment for arthralgia in <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>. No adverse events were observed in either group in <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>. <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> did not report adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008565-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Statin plus metformin compared to metformin alone for women with polycystic ovary syndrome not actively trying to conceive</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Statin plus metformin compared to metformin alone for women with polycystic ovary syndrome not actively trying to conceive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome not actively trying to conceive<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> statin + metformin<br/><b>Comparison:</b> metformin alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with metformin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with statin + metformin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resumption of menstrual regularity</b> (spontaneous menses per 6 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of spontaneous menses per 6 months was 1.1.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.6 menses more<br/>(0.08 fewer to 1.12 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resumption of spontaneous ovulation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> did not report spontaneous ovulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in hirsutism</b> (Ferriman‐Gallwey score) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in hirsutism after 6 months' treatment was −0.84.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.16 lower<br/>(0.91 lower to 0.59 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in acne severity</b> (scale of 0–3) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in acne severity after 6 months' treatment was −0.75.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.31 lower<br/>(0.67 lower to 0.05 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in testosterone level</b> (nmol/L) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level after 6 months' treatment was −0.52 nmol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 nmol/L lower<br/>(0.37 lower to 0.31 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported that no significant adverse events had occurred. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision (wide CI, small sample size, single study) and twice for very serious risk of bias concerns. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008565-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Statin plus oral contraceptive pill compared to oral contraceptive pill alone for women with polycystic ovary syndrome not actively trying to conceive</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Statin plus OCP compared to OCP for women with polycystic ovary syndrome not actively trying to conceive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome not actively trying to conceive<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> statin + OCP<br/><b>Comparison:</b> OCP </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with OCP</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with statin + OCP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resumption of menstrual regularity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report resumption of menstrual regularity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resumption of spontaneous ovulation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report on resumption of spontaneous ovulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in hirsutism</b> (Ferriman‐Gallwey score) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in hirsutism was −0.13.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.12 lower<br/>(0.41 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in acne severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report acne severity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Testosterone level</b> (change from baseline in nmol/L) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level (nmol/L) was −0.38 nmol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.82 nmol/L lower<br/>(1.38 lower to 0.26 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> reported that no significant adverse events occurred. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>*The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OCP:</b> oral contraceptive pill. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision (wide CI, small sample size, single study) and twice for very serious risk of bias concerns. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008565-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Statin compared to metformin for women with polycystic ovary syndrome not actively trying to conceive</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Statin compared to metformin for women with polycystic ovary syndrome not actively trying to conceive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome not actively trying to conceive<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> statin<br/><b>Comparison:</b> metformin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with metformin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with statin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resumption of menstrual regularity</b> (number of spontaneous menses per 6 months) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of spontaneous menses per 6 months after 6 months' treatment was 1.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.5 menses more<br/>(0.05 more to 1.05 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resumption of spontaneous ovulation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No studies reported resumption of spontaneous ovulation.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in hirsutism</b> (Ferriman‐Gallwey score) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in hirsutism after 6 months' treatment was −0.84.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.26 lower<br/>(0.97 lower to 0.45 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in acne severity</b> (scale of 0–3) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in acne score after 6 months' treatment was −0.75.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.18 lower<br/>(0.53 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in testosterone level</b> (nmol/L) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level after 6 months' treatment was −0.52 nmol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.24 nmol/L lower<br/>(0.58 lower to 0.1 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>The studies reported that no significant adverse events had occurred.<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision (wide CI, small sample size, single study) and twice for very serious risk of bias concerns.<br/><sup>b</sup><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported that six subjects using metformin experienced transient gastrointestinal side effects including diarrhoea; however, these side effects did not result in discontinuation of treatment. <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> reported that no participants experienced significant side effects. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008565-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Statin compared to oral contraceptive pill plus flutamide for women with polycystic ovary syndrome not actively trying to conceive</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Statin compared to OCP plus flutamide for women with polycystic ovary syndrome not actively trying to conceive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome not actively trying to conceive<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> statin<br/><b>Comparison:</b> OCP plus flutamide </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with OCP alone or in combination with another agent</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with statin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resumption of menstrual regularity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report resumption of menstrual regularity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resumption of spontaneous ovulation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report resumption of spontaneous ovulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in hirsutism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report hirsutism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in acne severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report acne severity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in testosterone level.</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report testosterone levels. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> reported that no women experienced any significant side effects. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OCP:</b> oral contraceptive pill. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008565-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008565-sec-0009"></div> <section id="CD008565-sec-0010"> <h3 class="title" id="CD008565-sec-0010">Description of the condition</h3> <p>Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, with a reported prevalence of 5% to 20% depending on the population studied and definitions used (<a href="./references#CD008565-bbs2-0039" title="AzzizR , CarminaE , ChenZ , DunaifA , LavenJS , LegroRS , et al. Polycystic ovary syndrome. Nature Reviews. Disease Primers2016;2:16057.">Azziz 2016</a>; <a href="./references#CD008565-bbs2-0042" title="BozdagG , MumusogluS , ZenginD , KarabulutE , YildizBO . The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction2016;31(12):2841-55.">Bozdag 2016</a>; <a href="./references#CD008565-bbs2-0057" title="FauserBC , TarlatzisBC , RebarRW , LegroRS , BalenAH , LoboR , et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility2012;97(1):28-38.e25.">Fauser 2012</a>; <a href="./references#CD008565-bbs2-0089" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602–18.">Teede 2018</a>). The clinical expression of PCOS varies but commonly includes oligo‐ovulation or anovulation, hyperandrogenism, and the presence of polycystic ovaries. According to the Rotterdam criteria, women must meet at least two of the following three criteria to receive a PCOS diagnosis (<a href="./references#CD008565-bbs2-0055" title="Rotterdam ESHRE/ASRM – Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertility and Sterility2004;81:19-25.">ESHRE/ASRM 2004</a>). </p> <p> <ol id="CD008565-list-0001"> <li> <p>Oligo‐ovulation or anovulation (infrequent or no ovulation)</p> </li> <li> <p>Clinical or biochemical signs of hyperandrogenism (elevated levels of androgens)</p> </li> <li> <p>Polycystic ovaries on ultrasound</p> </li> </ol> </p> <p>In addition, the diagnosing clinician must rule out other causes for hyperandrogenism (e.g. congenital adrenal hyperplasia, Cushing's syndrome, or androgen‐secreting tumours). </p> <p>Clinical and biochemical hyperandrogenism are prominent features in women with PCOS (<a href="./references#CD008565-bbs2-0054" title="Escobar-MorrealeHF . Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews. Endocrinology2018;14(5):270-84.">Escobar‐Morreale 2018</a>; <a href="./references#CD008565-bbs2-0061" title="GoodmanNF , CobinRH , FutterweitW , GlueckJS , LegroRS , CarminaE . American Association of Clinical Endocrinologists, American college of endocrinology, and Androgen Excess and PCOs society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome – part 1. Endocrine Practice2015;21(11):1291-300.">Goodman 2015</a>; <a href="./references#CD008565-bbs2-0085" title="SharmaA , WeltCK . Practical approach to hyperandrogenism in women. The Medical Clinics of North America2021;105(6):1099-116.">Sharma 2021</a>; <a href="./references#CD008565-bbs2-0089" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602–18.">Teede 2018</a>), with a reported prevalence of 60% to 80% (<a href="./references#CD008565-bbs2-0045" title="ChinHB , MarshEE , HallJE , BairdDD . Prevalence of hirsutism among reproductive-aged African American women. Journal of Women's Health2021;30(11):1580-7.">Chin 2021</a>; <a href="./references#CD008565-bbs2-0088" title="SpritzerPM , BaroneCR , OliveiraFB . Hirsutism in polycystic ovary syndrome: Pathophysiology and management. Current pharmaceutical design2016;22(36):5603-13.">Spritzer 2016</a>). Clinical features of hyperandrogenism include hirsutism (excess male‐pattern hair growth), acne, and androgenetic alopecia (<a href="./references#CD008565-bbs2-0054" title="Escobar-MorrealeHF . Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews. Endocrinology2018;14(5):270-84.">Escobar‐Morreale 2018</a>; <a href="./references#CD008565-bbs2-0058" title="FranikG , BizońA , WłochS , KowalczykK , Biernacka-BartnikA , MadejP . Hormonal and metabolic aspects of acne vulgaris in women with polycystic ovary syndrome. European Review for Medical and Pharmacological Sciences2018;22(14):4411-8.">Franik 2018</a>; <a href="./references#CD008565-bbs2-0059" title="GarziaE , GalianoV , MarfiaG , NavoneS , GrossiE , MarconiAM . Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients. Reproductive Biology and Endocrinology2022;20(1):6.">Garzia 2022</a>). Androgen excess represents an independent risk factor for development of hypertension and increased cardiovascular risk in women with PCOS (<a href="./references#CD008565-bbs2-0039" title="AzzizR , CarminaE , ChenZ , DunaifA , LavenJS , LegroRS , et al. Polycystic ovary syndrome. Nature Reviews. Disease Primers2016;2:16057.">Azziz 2016</a>; <a href="./references#CD008565-bbs2-0041" title="BarreaL , MuscogiuriG , PuglieseG , Alteriis G de, ColaoA , SavastanoS . Metabolically healthy obesity (MHO) vs. metabolically unhealthy obesity (MUO) phenotypes in PCOS: association with endocrine-metabolic profile, adherence to the Mediterranean diet, and body composition. Nutrients2021;13(11):3925.">Barrea 2021</a>), and it can worsen metabolic disorders such as obesity, insulin resistance, and glucose intolerance in this population (<a href="./references#CD008565-bbs2-0053" title="DumesicDA , AbbottDH , SanchitaS , ChazenbalkGD . Endocrine-metabolic dysfunction in polycystic ovary syndrome: an evolutionary perspective. Current Opinion in Endocrine and Metabolic Research2020;12:41-8.">Dumesic 2020</a>; <a href="./references#CD008565-bbs2-0060" title="GilbertEW , TayCT , HiamDS , TeedeHJ , MoranLJ . Comorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews. Clinical Endocrinology (Oxford)2018;89(6):683-99.">Gilbert 2018</a>). These metabolic disorders are involved in both the pathogenesis and the progression of the disease (<a href="./references#CD008565-bbs2-0037" title="ArmaniniD , BoscaroM , BordinL , SabbadinC . Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism. International Journal of Molecular Sciences2022;23(8):4110.">Armanini 2022</a>; <a href="./references#CD008565-bbs2-0039" title="AzzizR , CarminaE , ChenZ , DunaifA , LavenJS , LegroRS , et al. Polycystic ovary syndrome. Nature Reviews. Disease Primers2016;2:16057.">Azziz 2016</a>; <a href="./references#CD008565-bbs2-0051" title="DingHG , ZhangJ , ZhangF , ZhangSO , ChenXZ , LiangWQ , et al. Resistance to the insulin and elevated level of androgen: a major cause of polycystic ovary syndrome. Frontiers in Endocrinology2021;12:741764.">Ding 2021</a>; <a href="./references#CD008565-bbs2-0056" title="EzehU , Pisarska MD , AzzizR . Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome. Human Reproduction2022;37(3):553-64.">Ezeh 2022</a>; <a href="./references#CD008565-bbs2-0078" title="RosenfieldRL , EhrmannDA . The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews2016;37(5):467-520.">Rosenfield 2016</a>; <a href="./references#CD008565-bbs2-0082" title="Sanchez-GarridoMA , Tena-SempereM . Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Molecular Metabolism2020;35:100937.">Sanchez‐Garrido 2020</a>). Obesity and severe acne vulgaris can also lead to psychological sequelae (<a href="./references#CD008565-bbs2-0050" title="DamoneAL , JohamAE , LoxtonD , EarnestA , TeedeHJ , MoranLJ . Depression, anxiety and perceived stress in women with and without PCOS: a community-based study. Psychological Medicine2019;49(9):1510-20.">Damone 2019</a>; <a href="./references#CD008565-bbs2-0067" title="KolheJV , ChhipaAS , ButaniS , ChavdaV , PatelSS . PCOS and depression: common links and potential targets. Reproductive Sciences2022;29(11):3106-23.">Kolhe 2022</a>). Thus, hyperandrogenism is one main target for treatment to improve quality of life and decrease morbidity. </p> <p>Over the longer term, PCOS is associated with a broad range of adverse sequelae, including dyslipidaemia (abnormal lipid levels in the blood), hypertension, insulin resistance with compensatory hyperinsulinaemia, gestational diabetes, and type 2 diabetes mellitus (<a href="./references#CD008565-bbs2-0039" title="AzzizR , CarminaE , ChenZ , DunaifA , LavenJS , LegroRS , et al. Polycystic ovary syndrome. Nature Reviews. Disease Primers2016;2:16057.">Azziz 2016</a>; <a href="./references#CD008565-bbs2-0047" title="CooneyLG , DokrasA . Beyond fertility: polycystic ovary syndrome and long-term health. Fertility and Sterility2018;110(5):794-809.">Cooney 2018</a>; <a href="./references#CD008565-bbs2-0052" title="DohertyDA , NewnhamJP , BowerC , HartR . Implications of polycystic ovary syndrome for pregnancy and for the health of offspring. Obstetrics and Gynecology2015;125(6):1397-406.">Doherty 2015</a>). Experts believe than women with PCOS have an increased cardiovascular risk, mediated mostly by insulin resistance, as well as by hormonal and metabolic processes (<a href="./references#CD008565-bbs2-0040" title="AzzizR . Polycystic ovary syndrome. Obstetrics and Gynecology2018;132(2):321-36.">Azziz 2018</a>; <a href="./references#CD008565-bbs2-0063" title="HartR , DohertyDA . The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage. Journal of Clinical Endocrinology and Metabolism2015;100(3):911-9. [PMID: 25532045]">Hart 2015</a>; <a href="./references#CD008565-bbs2-0074" title="OsibogunO , OgunmorotiO , MichosED . Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends in Cardiovascular Medicine2020;30(7):399-404.">Osibogun 2020</a>; <a href="./references#CD008565-bbs2-0090" title="WekkerV , vanDammenL , KoningA , Heida KY , Painter RC , LimpensJ , et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Human Reproduction Update2020;26(6):942-60.">Wekker 2020</a>). Chronic low‐grade inflammation, such as increased white blood cell count and high levels of C‐reactive protein (CRP) may also be associated with long‐term metabolic complications and high cardiovascular risk (<a href="./references#CD008565-bbs2-0074" title="OsibogunO , OgunmorotiO , MichosED . Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends in Cardiovascular Medicine2020;30(7):399-404.">Osibogun 2020</a>; <a href="./references#CD008565-bbs2-0080" title="RudnickaE , SuchtaK , GrymowiczMA , Calik-KsepkaA , SmolarczykK , DuszewskaAM , et al. Chronic low grade inflammation in pathogenesis of PCOS. International Journal of Molecular Sciences2021;22(7):3789.">Rudnicka 2021</a>). The effect of menopausal transition on the long‐term health consequences of PCOS is mostly uncertain, owing to limited evidence. The PCOS phenotype of affected women improves with ageing (<a href="./references#CD008565-bbs2-0071" title="MuktaA , SudwitaS , PallaviL , RituS , SimranD . Polycystic ovarian syndrome in aging women: An observational study. Cureus2022;14(9):e29776.">Mukta 2022</a>; <a href="./references#CD008565-bbs2-0072" title="MumusogluS , YildizBO . Metabolic syndrome during menopause. Current Vascular Pharmacology2019;17(6):595-603.">Mumusoglu 2019</a>). Therefore, the differences in the cardiometabolic risk profiles between women with PCOS and the general population seem to decrease after menopause. </p> </section> <section id="CD008565-sec-0011"> <h3 class="title" id="CD008565-sec-0011">Description of the intervention</h3> <p>The 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors (or statins, such as atorvastatin and simvastatin) are amongst the most prescribed drugs in the world. Statins are prescribed for dyslipidaemia because they lower total cholesterol and low‐density lipoprotein (LDL) cholesterol levels (<a href="./references#CD008565-bbs2-0035" title="AdamsSP , TsangM , WrightJM . Atorvastatin for lowering lipids. Cochrane Database of Systematic Reviews2015, Issue 3. Art. No: CD008226. [DOI: 10.1002/14651858.CD008226.pub3]">Adams 2015</a>). Research has attributed the effects of statins to reduced cholesterol biosynthesis through competitive inhibition of HMG‐CoA reductase, which converts HMG‐CoA to L‐mevalonate. Statin therapy reduces the risk of all‐cause mortality and cardiovascular events (such as myocardial infarction and stroke) in adults at increased cardiovascular risk (<a href="./references#CD008565-bbs2-0046" title="ChouR , CantorA , DanaT , WagnerJ , AhmedAY , FuR , et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US preventive services task force. JAMA2022;328(8):754-71.">Chou 2022</a>). </p> </section> <section id="CD008565-sec-0012"> <h3 class="title" id="CD008565-sec-0012">How the intervention might work</h3> <p>Statins inhibit the synthesis of mevalonate (the key precursor to cholesterol biosynthesis) and ultimately inhibit androgen synthesis. Steroidogenesis within the ovary begins in the theca cell. Lipoprotein receptors on the cell surface, for high‐density lipoprotein (HDL) and LDL, transport cholesterol into the cell to act as the substrate for steroid synthesis. Steroid synthesis within the theca cell begins with synthesis of the androgen androstenedione, which then may be converted to oestrogen by aromatisation within the granulosa cells, or to testosterone by reductases. Modification though increased or decreased availability of lipoprotein to the theca cell receptors can augment or decrease subsequent androgen synthesis (<a href="./references#CD008565-bbs2-0083" title="SchifferL , BarnardL , BaranowskiES , GilliganLC , TaylorAE , ArltW , et al. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review. The Journal of Steroid Biochemistry and Molecular Biology2019;194:105439.">Schiffer 2019</a>). Since statins decrease the availability of cholesterol (an essential substrate for testosterone production), they may reduce serum testosterone levels. Elevated testosterone is one important factor that inhibits ovulation and leads to menstrual disorders in PCOS. Therefore, statins may benefit women with PCOS who have hyperandrogenism, by restoring ovulation and regulating menstrual cycles. </p> <p>Moreover, according to several studies, statins have immunomodulatory properties with potential beneficial effects beyond their lipid‐lowering properties (<a href="./references#CD008565-bbs2-0073" title="OesterleA , LaufsU , LiaoJK . Pleiotropic effects of statins on the cardiovascular system. Circulation Research2017;120(1):229-43.">Oesterle 2017</a>; <a href="./references#CD008565-bbs2-0087" title="SheridanA , Wheeler-JonesCPD , GageMC . The immunomodulatory effects of statins on macrophages. Immunology2022;2(2):317-43.">Sheridan 2022</a>; <a href="./references#CD008565-bbs2-0092" title="ZeiserR . Immune modulatory effects of statins. Immunology2018;154(1):69-75.">Zeiser 2018</a>). Data from clinical trials have demonstrated that statin therapy leads to a decrease in the level of the inflammatory marker CRP (<a href="./references#CD008565-bbs2-0075" title="PlengeJK , HernandezTL , WeilKM , PoirierP , GrunwaldGK , MarcovinaSM , et al. Simvastatin lowers C-reactive protein within 14 Days. Circulation2002;106(12):1447-52.">Plenge 2002</a>; <a href="./references#CD008565-bbs2-0077" title="RidkerPM , CannonCP , MorrowD , RifaiN , RoseLM , McCabeCH , et al. C-reactive protein levels and outcomes after statin therapy. New England Journal of Medicine2005;352(1):20-8.">Ridker 2005</a>). </p> </section> <section id="CD008565-sec-0013"> <h3 class="title" id="CD008565-sec-0013">Why it is important to do this review</h3> <p>PCOS is a complex endocrine condition. The international evidence‐based guideline for the assessment and management of PCOS acknowledges that women with this condition have increased cardiovascular disease risk factors, though good evidence from clinical trials is lacking (<a href="./references#CD008565-bbs2-0034" title="American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. ACOG practice bulletin No. 194: polycystic ovary syndrome. Obstetrics and Gynecology2018;131(6):e157-71.">ACOG 2018</a>; <a href="./references#CD008565-bbs2-0089" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction2018;33(9):1602–18.">Teede 2018</a>). Furthermore, long‐term statin use has been linked to an increased risk of type 2 diabetes (<a href="./references#CD008565-bbs2-0049" title="CrandallJP , MatherK , RajpathakSN , GoldbergRB , WatsonK , FooS , et al. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open2017;10(5):e000438.">Crandall 2017</a>). This is an update of a Cochrane Review published in 2011 (<a href="./references#CD008565-bbs2-0094" title="RavalAD , HunterT , StuckeyB , HartRJ . Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database of Systematic Reviews2011, Issue 10. Art. No: CD008565. [DOI: 10.1002/14651858.CD008565.pub2]">Raval 2011</a>). Several new studies evaluating statins in PCOS have been published since the last version of this review. There is a need to determine any potential beneficial or harmful effects of statins, alone or in combination with other agents, on metabolic and hormonal variables affecting clinical outcomes in women with PCOS. This may have implications for treatment of common presenting features of the condition. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008565-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008565-sec-0014"></div> <p>To assess the efficacy and safety of statin therapy in women with polycystic ovary syndrome who are not actively trying to conceive. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008565-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008565-sec-0015"></div> <section id="CD008565-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008565-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) that evaluated any statin (e.g. atorvastatin, simvastatin, pravastatin, rosuvastatin) versus placebo, no treatment, or another drug; or any statin in combination with another drug versus the other drug alone. We excluded quasi‐ or pseudo‐RCTs. Cross‐over trials were eligible, but we only used data from the first phase (before cross‐over). </p> </section> <section id="CD008565-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies of women with PCOS who were not actively trying to conceive, as statins are contraindicated in pregnancy. Eligible criteria for PCOS diagnosis were the European Society for Human Reproduction and Embryology (ESHRE)‐ and American Society for Reproductive Medicine (ASRM)‐sponsored PCOS Consensus Workshop criteria (the Rotterdam criteria; <a href="./references#CD008565-bbs2-0055" title="Rotterdam ESHRE/ASRM – Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertility and Sterility2004;81:19-25.">ESHRE/ASRM 2004</a>; <a href="./references#CD008565-bbs2-0079" title="Rotterdam ESHRE/ASRM – Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertility and Sterility2004;81:19-25.">Rotterdam 2004</a>) or the US National Institutes of Health (NIH) consensus criteria (<a href="./references#CD008565-bbs2-0091" title="ZawadzkiJ , DunaifA . Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: DunaifA , GivensJ , HaseltineF , MerriamG , editors(s). Polycystic Ovarian Syndrome. Boston: Blackwell, 1992:377-84.">Zawadzki 1992</a>). </p> <p>If the study report did not clearly state the diagnostic criteria, we contacted the study authors for clarification. If this information was unavailable, we excluded the study. Changes in diagnostic criteria might produce variability in the clinical characteristics of the women included in the studies and the results obtained. We planned to consider, document, and explore these changes in a sensitivity analysis. </p> </section> <section id="CD008565-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The following comparisons were eligible for this review.</p> <p> <ol id="CD008565-list-0002"> <li> <p>Statin versus placebo or no treatment</p> </li> <li> <p>Statin plus another agent versus the other agent alone</p> </li> <li> <p>Statin versus another agent</p> </li> </ol> </p> </section> <section id="CD008565-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD008565-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008565-list-0003"> <li> <p>Resumption of menstrual regularity (i.e. initiation of menses or significant shortening of cycles, number of women with resumption of normal menstrual cycle (between 21 and 34 days), or as defined by study authors). </p> </li> <li> <p>Resumption of spontaneous ovulation documented by biochemical methods (i.e. evidence of serum progesterone in the luteal range for the reference laboratory; or rise in basal body temperature of more than 0.4 ºC, as measured on a basal body temperature chart, for 10 days or more). </p> </li> </ol> </p> </section> <section id="CD008565-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008565-list-0004"> <li> <p>Improvement in body composition</p> <ol id="CD008565-list-0005"> <li> <p>Body mass index (BMI; kg/m<sup>2</sup>; lower is better) </p> </li> <li> <p>Waist circumference (cm; lower is better)</p> </li> <li> <p>Waist‐hip ratio (WHR; lower is better)</p> </li> </ol> </li> <li> <p>Improvement in hirsutism (Ferriman‐Gallwey score; lower is better)</p> </li> <li> <p>Improvement in acne severity (clinical score as reported by study authors)</p> </li> <li> <p>Improvement in testosterone level (nmol/L; lower is better)</p> </li> <li> <p>Improvement in lipid profile</p> <ol id="CD008565-list-0006"> <li> <p>Total cholesterol (mmol/L; lower is better)</p> </li> <li> <p>LDL cholesterol (mmol/L; lower is better)</p> </li> <li> <p>HDL cholesterol (mmol/L; higher is better)</p> </li> <li> <p>Triglycerides (mmol/L; lower is better)</p> </li> </ol> </li> <li> <p>Improvement in high‐sensitivity CRP (hs‐CRP; nmol/L; lower is better)</p> </li> <li> <p>Improvement in insulin sensitivity</p> <ol id="CD008565-list-0007"> <li> <p>Fasting insulin (µIU/mL; lower is better)</p> </li> <li> <p>Glucose/insulin ratio (lower is better)</p> </li> <li> <p>Homeostatic model assessment for insulin resistance (HOMA‐IR; lower is better)</p> </li> <li> <p>Standard measures from euglycaemic clamps or intravenous glucose tolerance tests</p> </li> </ol> </li> <li> <p>Adverse effects of statins: all serious and non‐serious adverse events, especially rhabdomyolysis, creatinine kinase levels over 10 times the upper limit of normal values, and liver aminotransferase levels over three times the upper limit of normal values. </p> </li> </ol> </p> </section> </section> </section> <section id="CD008565-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs that evaluated statins in women with PCOS not actively trying to conceive, without language restriction, and in consultation with the Cochrane Gynaecology and Fertility (CGF) Group Information Specialist (Marian Showell). </p> <section id="CD008565-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases for relevant studies.</p> <p> <ol id="CD008565-list-0008"> <li> <p>CGF Specialised Register of Controlled Trials, ProCite platform (searched 7 November 2022; <a href="./appendices#CD008565-sec-0196">Appendix 1</a>) </p> </li> <li> <p>CENTRAL via the Cochrane Register of Studies Online (CRSO), web platform (searched 7 November 2022; <a href="./appendices#CD008565-sec-0197">Appendix 2</a>) </p> </li> <li> <p>MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid platform (1946 to 7 November 2022; <a href="./appendices#CD008565-sec-0198">Appendix 3</a>) </p> </li> <li> <p>Embase, Ovid platform (1980 to 7 November 2022; <a href="./appendices#CD008565-sec-0199">Appendix 4</a>) </p> </li> <li> <p>PsycINFO, Ovid platform (1806 to 7 November 2022; <a href="./appendices#CD008565-sec-0200">Appendix 5</a>) </p> </li> <li> <p>CINAHL Plus (Cumulative Index to Nursing and Allied Health Literature), EBSCO platform (1961 to 25 September 2019 (all later CINAHL references are included in the CENTRAL search output); <a href="./appendices#CD008565-sec-0201">Appendix 6</a>) </p> </li> </ol> </p> <p>We carried out initial searches to July 2011, then updated the searches in September 2019 and November 2022, with assistance from the CGF Group Information Specialist. </p> </section> <section id="CD008565-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the following trials registers for ongoing trials.</p> <p> <ol id="CD008565-list-0009"> <li> <p>NIH Ongoing Trials Register ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>) </p> </li> <li> <p>CenterWatch Clinical Trials Listing Service (<a href="https://www.centerwatch.com/" target="_blank">www.centerwatch.com/</a>) </p> </li> <li> <p>NIH Clinical Center: Search the Studies (<a href="http://clinicalstudies.info.nih.gov/" target="_blank">clinicalstudies.info.nih.gov/</a>) </p> </li> </ol> </p> <p>We also checked the reference lists of relevant trials and systematic reviews retrieved by the search and contacted experts in the field to obtain additional data. We handsearched journals and conference proceedings not covered in the CGF register, in liaison with the CGF Information Specialist. Lastly, we searched Google Scholar for recent trials not yet indexed in the major databases. </p> </section> </section> <section id="CD008565-sec-0026"> <h3 class="title" id="CD008565-sec-0026">Data collection and analysis</h3> <section id="CD008565-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (TX and EK or EBK) independently screened the titles and abstracts of the records returned by the search and retrieved the full‐text articles of all potentially relevant studies. The same two review authors independently assessed each of these studies for inclusion in the review using <a href="./references#CD008565-bbs2-0048" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed May 2022. Available at covidence.org.">Covidence</a>. We resolved any disagreements by discussion or by involving a third review author (EBK when the selection was made by TX and EK). We excluded studies that did not meet the eligibility criteria and recorded the reasons for exclusion in the <a href="./references#CD008565-sec-0212" title="">Characteristics of excluded studies</a> table. </p> <p>We screened all potentially eligible studies using the checklist of the Pregnancy &amp; Childbirth group (<a href="./references#CD008565-bbs2-0036" title="AlfirevicZ , KellieFJ , StewartF , JonesL , HampsonL , on behalf of Pregnancy and Childbirth Editorial Board. Identifying and handling potentially untrustworthy trials in Pregnancy and Childbirth Cochrane Reviews. web.archive.org/web/20221228171245/pregnancy.cochrane.org/sites/pregnancy.cochrane.org/files/public/uploads/identifying_and_handling_potentially_untrustworthy_trials_v_2.4_-_20_july_2021.pdf.">Alfirevic 2021</a>). Any studies that had been registered and completed but not (yet) published, as well as potentially problematic studies according to the integrity checklist, were listed as awaiting classification (<a href="./references#CD008565-bbs1-0003" title="">Studies awaiting classification</a>). </p> </section> <section id="CD008565-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (TX and EF or EK) independently entered data into a data extraction form supplied by the Cochrane Gynaecology and Fertility Group. We collected data on study characteristics, including methods, participants, interventions, and outcomes. We resolved any disagreements by referring to the trial report and through discussion and consultation with a third author (MC). If data were missing from trial reports, or the reported data were insufficient, we contacted the trial authors for additional information. Where possible, we extracted data to allow an intention‐to‐treat (ITT) analysis (including all women in the groups to which they were originally randomly assigned). If the number randomised and the number analysed were inconsistent, we calculated the percentage loss to follow‐up and reported this information in an additional table. The review authors were not blinded to the names of trialists, journals, or institutions. <a href="#CD008565-tbl-0006">Table 1</a> shows the conversion factors used to make uniform units of the parameters. </p> <div class="table" id="CD008565-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Conversion factors</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Convert from</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Convert to</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conversion factor</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholesterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.026</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>μIU/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1667</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.056</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Testosterone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03467</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High‐sensitivity C‐reactive protein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.524</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sqrt n</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(upper limit−lower limit)/3.92</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD008565-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (TX and EF or EK) independently assessed the included studies for risk of bias using the Cochrane risk of bias assessment tool (RoB 1), which covers the following domains (<a href="./references#CD008565-bbs2-0064" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). </p> <p> <ol id="CD008565-list-0010"> <li> <p>Selection bias (random sequence generation and allocation concealment)</p> </li> <li> <p>Performance bias (blinding of participants and personnel)</p> </li> <li> <p>Detection bias (blinding of outcome assessors)</p> </li> <li> <p>Attrition bias (incomplete outcome data)</p> </li> <li> <p>Reporting bias (selective reporting)</p> </li> <li> <p>Other potential sources of bias</p> </li> </ol> </p> <p>We rated studies as being at high, low, or unclear risk of bias for each domain, as recommended in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008565-bbs2-0064" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). We assigned an 'unclear' judgement where trials provided insufficient detail, or the risk of bias was unknown, or the domain was irrelevant to the study. We resolved any disagreements by discussion with a third review author (EBK). We described all judgements fully and presented our conclusions in the <a href="./references#CD008565-sec-0211" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD008565-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We performed statistical analyses according to the statistical guidelines provided in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD008565-bbs2-0065" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022</a>). For dichotomous outcomes, we planned to report the odds ratio (OR), together with its 95% confidence interval (CI). For continuous outcomes, we used the mean difference (MD) with its 95% CI. </p> </section> <section id="CD008565-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We used data from only the first phase of cross‐over trials (i.e. before cross‐over). We excluded any cross‐over trials that did not provide results at this time point. </p> </section> <section id="CD008565-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted trial authors to obtain descriptive statistics on the outcomes of interest where necessary. In addition, if trial reports provided a narrative summary of an outcome measure (e.g. 'no difference in menstrual regularity') without the number of events, we recorded the summary in the <a href="./full#CD008565-sec-0039">Results</a> section. We found no studies in which only a subset of participants was eligible for this review. </p> </section> <section id="CD008565-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity by calculating the I<sup>2</sup> statistic, considering an I<sup>2</sup> value greater than 50% to be indicative of substantial heterogeneity (<a href="./references#CD008565-bbs2-0065" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD008565-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>Had we included more than 10 studies in a meta‐analysis, we would have assessed publication bias by creating a funnel plot. </p> </section> <section id="CD008565-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Where there were sufficient data, we calculated a summary statistic for each outcome with respect to the interventions (as described in <a href="#CD008565-sec-0019">Types of interventions</a>) using a fixed‐effect model and RevMan 5.4.1 software (<a href="./references#CD008565-bbs2-0076" title="Review Manager 5 (RevMan 5). Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). In cases of substantial heterogeneity, we used a random‐effects model. </p> </section> <section id="CD008565-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct subgroup analyses to explore sources of heterogeneity (based on type of statin, type of comparison, duration of intervention, and ethnicity of participants). </p> </section> <section id="CD008565-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to examine the stability of the results in relation to several factors (including comedication, quality of allocation concealment, blinding, ITT analysis, source of funding, different diagnostic criteria of PCOS, and obesity) if sufficient data were available. </p> <p>We also planned sensitivity analyses restricted to studies with low risk of selection bias (random sequence generation and allocation concealment) for all primary outcomes. </p> </section> <section id="CD008565-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared summary of findings tables using GRADEpro software (<a href="./references#CD008565-bbs2-0062" title="GRADEpro GDT. Version accessed November 2022. Hamilton (ON): GRADE Working Group, McMaster University, 2014.">GRADEpro GDT 2014</a>), and we assessed the certainty of evidence using GRADE methodology (<a href="./references#CD008565-bbs2-0081" title="RyanR , HillS . How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group, Version 3.0 December 2016. Available at cccrg.cochrane.org/author-resources.">Ryan 2016</a>; <a href="./references#CD008565-bbs2-0084" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook.">Schünemann 2013</a>). The tables presented the overall certainty of the body of evidence for the main review outcomes (resumption of menstrual regularity, resumption of spontaneous ovulation, hirsutism, acne, testosterone levels, and adverse effects) for the main review comparisons (statin versus placebo or no treatment, statin plus another agent versus the other agent alone, statin versus another agent). Two review authors (TX and EK) independently assessed the certainty of the evidence as high, moderate, low, or very low based on the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness, and publication bias). We resolved any disagreements by discussion or by consulting a third review author (EBK). We provided justifications for the GRADE judgements in footnotes to the summary of findings tables. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008565-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008565-sec-0039"></div> <section id="CD008565-sec-0040"> <h3 class="title">Description of studies</h3> <p>See the <a href="./references#CD008565-sec-0211" title="">Characteristics of included studies</a>, <a href="./references#CD008565-bbs1-0003" title="">Studies awaiting classification</a>, and <a href="./references#CD008565-sec-0212" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD008565-sec-0041"> <h4 class="title">Results of the search</h4> <p>The first version of this review included four trials. In the current update, we retrieved 244 records (after removal of duplicates), of which we discarded 206 during title and abstract screening. We then retrieved and assessed 38 full‐text articles, excluding 18 (14 trials). Two new trials (five records) were eligible for inclusion. We identified seven additional records of previously included studies. Eight trials are awaiting classification. <a href="#CD008565-fig-0001">Figure 1</a> shows the study selection process in a PRISMA flow diagram. </p> <div class="figure" id="CD008565-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD008565-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD008565-sec-0042"> <h4 class="title">Included studies</h4> <p>We included six RCTs: two identified in this update (<a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>; <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>) and four from the previous version of the review (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). </p> <section id="CD008565-sec-0043"> <h5 class="title">Design, setting, and funding</h5> <p>Five RCTs had a parallel‐group design, and <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> had a cross‐over design (we included the data from the first phase, before cross‐over). Sample sizes ranged from 20 to 139 women. All studies were single‐centre RCTs. Four took place in European countries (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>), one in the USA (<a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>), and one in Iran (<a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>). All participants were recruited within university‐associated medical centres or hospitals. </p> <p>Pharmaceutical companies provided the study drugs for five studies (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>; <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> was supported by the Polish State Committee for Scientific Research and the National Institute of Child Health and Human Development (NICHD); <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> was supported by an NIH grant; <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> by the Academy of Finland and other funding bodies; <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> by an NIH grant, NICHD, a construction grant to Pennsylvania State University, and a research grant from Pfizer; and <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> by an unrestricted grant from the pharmaceutical company Pfizer. <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> received institutional funding. </p> </section> <section id="CD008565-sec-0044"> <h5 class="title">Participants</h5> <p>A total of 396 women were randomised to either statin treatment, placebo, or active control, and 374 women completed the studies. A total of 265 women took part in the European studies, 20 in the USA study, and 111 in the Iranian study. Only <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> stated age as an inclusion criterion. <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> had the youngest participants (mean age 23.9 years), and <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> had the oldest participants (mean age 39 years). The mean BMI of participants was in the normal range (20 kg/m<sup>2</sup> to 25 kg/m<sup>2</sup>) in two studies (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>), and in the overweight or obese range (more than 25 kg/m<sup>2</sup>) in the remaining studies. The mean baseline total serum testosterone levels were highest in <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> (mean 4.1 nmol/L to 4.4 nmol/L) and lowest in <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> (mean 0.9 nmol/L to 1.4 nmol/L). In <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> and <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>, baseline mean testosterone levels differed between the study arms. See <a href="#CD008565-tbl-0007">Table 2</a> for details. </p> <div class="table" id="CD008565-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study group (n)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline demographics, mean (SD)</b> </p> </th> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline biochemistry, mean (SD)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BMI (kg/m<sup>2</sup>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total T (nmol/L)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>FI <b>(µIU/ml)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TC (mmol/L)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>HDL (mmol/L)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LDL (mmol/L)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TG (mmol/L)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sim + met (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.3 (4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.8 (5.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.95 (0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.10 (5.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.79 (0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.68 (0.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.64 (0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: sim (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.3 (4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.5 (4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.91 (0.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.90 (4.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.96 (0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.79 (0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.80 (0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: met (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0 (4.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.7 (4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.91 (0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.10 (4.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.53 (0.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.57 (0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.51 (0.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.51)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sim + OCP (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.0 (3.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.7 (2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.96 (0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (3.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.02 (0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.69 (0.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.78 (0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: OCP (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.8 (3.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8 (3.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.62 (0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 (4.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.86 (1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.59 (0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.76 (0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.08 (0.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sim (34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2 (8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.9 (4.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.21 (0.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: OCP + flu (34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.0 (7.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.8 (4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: met (34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2 (8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.8 (4.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: AT (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.5 (5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.4 (8.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.30 (10.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.20 (0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.52 (0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.30 (0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (0.50)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: P (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5 (4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7 (4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.10 (3.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.90 (0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.50 (0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.00 (1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: AT (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.8 (4.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.1 (11.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.13 (0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6 (10.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.58 (1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.15 (0.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.64 (0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.73 (0.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: P (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.4 (5.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.0 (10.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.20 (1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8 (9.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.24 (0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.40 (0.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.41 (0.60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: AT (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6 (5.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.2 (6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.10 (0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.6 (7.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.60 (0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.90 (0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34 (0.35)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: P (18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8 (7.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.9 (5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.40 (0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4 (8.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.50 (0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.70 (0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.39 (1.02)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>a. 86% of participants had irregular menstrual cycle (≤ 8 spontaneous cycles/year), 79% had hirsutism, and 82% had acne.<br/>b. 73% of participants had irregular menstrual cycle.<br/>AT: atorvastatin; BMI: body mass index; C: control; I: intervention; FI: fasting insulin; flu: flutamide; HDL: high‐density lipoprotein cholesterol; LDL: low‐density lipoprotein cholesterol; met: metformin; NR: not reported; sim: simvastatin; SD: standard deviation; T: testosterone; TC: total cholesterol; TG: total glucose. </p> </div> </div> <p>Regarding baseline PCOS criteria, <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported that 79% of women had significant hirsutism, and 85% had oligomenorrhoea. </p> <p>All the studies provided the diagnostic criteria for PCOS. The main components of diagnostic criteria were as follows. </p> <p> <ol id="CD008565-list-0011"> <li> <p>Clinical or biochemical signs of hyperandrogenism</p> </li> <li> <p>Oligo‐ovulation or anovulation</p> </li> <li> <p>Polycystic ovaries</p> </li> </ol> </p> <p><a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> included women with all three components; <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> included women with any two of the three components, as per the internationally agreed definition of PCOS (<a href="./references#CD008565-bbs2-0055" title="Rotterdam ESHRE/ASRM – Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertility and Sterility2004;81:19-25.">ESHRE/ASRM 2004</a>); and <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> and <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> included women who met the modified Rotterdam criteria (the first component plus either of the other two components). <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> and <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> included women with PCOS defined using the 1990 NIH criteria. <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> included only unmarried women. </p> <p>All the studies confirmed absence of non‐classical 21‐hydroxylase deficiency, hyperprolactinaemia, Cushing's disease, and androgen‐secreting tumours. <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> included women with PCOS who had LDL cholesterol levels above 100 mg/dL. The remaining studies provided no data on comorbidities. <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> reported use of the oral contraceptive pill (OCP) by one woman in the statin group and use of antihypertensives by one woman in each of the two groups. In addition, no participants in <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> used metformin or other medication that could affect outcomes. <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> evaluated therapy‐naive women, and the remaining studies provided no details about previous medication. However, <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>, <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>, and <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> required that all participants refrain from using any form of oral contraceptives, other steroid hormones, and any other treatments likely to affect ovarian function, insulin sensitivity, or lipid profile three months before enrolment. <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> provided no details about treatment before the study. </p> <p>All studies excluded women who were using sex hormones or drugs known to affect lipid metabolism, ovarian function, or insulin sensitivity. Four studies excluded women with type 2 diabetes mellitus or thyroid disease (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>; <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>). In addition, <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> excluded women with active liver disease or thyroid disease, and woman who were pregnant or breastfeeding. <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> excluded women with abnormal kidney or liver function. </p> </section> <section id="CD008565-sec-0045"> <h5 class="title">Interventions</h5> <section id="CD008565-sec-0046"> <h6 class="title">Comparisons</h6> <p>Three studies investigated statin monotherapy versus placebo (<a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>; <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>), <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> evaluated statin combined with metformin versus metformin alone, <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> evaluated statin combined with OCP versus OCP alone, and two studies investigated statin monotherapy versus metformin (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>). <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> also evaluated statin monotherapy versus OCP plus flutamide. </p> <section id="CD008565-sec-0047"> <p><b>Monotherapy</b></p> <p><a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> and <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> compared atorvastatin (20 mg per day, orally) versus placebo, and <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> compared atorvastatin (60 mg per day, orally) versus placebo. <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> compared simvastatin (20 mg per day, orally) versus metformin (500 mg three times per day, orally), and <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> compared simvastatin (20 mg per day, orally) versus metformin (850 mg twice per day, orally). </p> </section> <section id="CD008565-sec-0048"> <p><b>Combination therapy</b></p> <p>Two studies evaluated statin combination therapy: <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> evaluated simvastatin (20 mg per day, orally) plus metformin (850 mg twice per day, orally) versus metformin (850 mg twice per day). <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> evaluated simvastatin (20 mg/day, orally) plus OCP (ethinyl oestradiol 20 µg and desogestrel 150 µg, orally) versus the same OCP alone. </p> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> evaluated simvastatin versus OCP (levonorgestrel 0.15 mg and ethinyl oestradiol 0.03 mg, daily) plus flutamide (62.5 mg daily). </p> </section> </section> <section id="CD008565-sec-0049"> <h6 class="title">Follow‐up</h6> <p>Three studies measured outcomes after approximately three months of treatment (<a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>), and three studies measured outcomes after six months of treatment (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>; <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>). Treatment duration was six weeks in <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>. </p> </section> </section> <section id="CD008565-sec-0050"> <h5 class="title">Outcomes</h5> <p>All studies reported biochemical or physiological measures as their primary outcomes. With respect to the primary outcomes of this review, two studies reported resumption of menstrual regularity, though they had not prespecified this outcome in any study publication (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>); and no studies reported spontaneous ovulation. </p> <p>Serum testosterone level was the stated primary outcome of three studies (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>). Primary outcomes in the other studies were insulin sensitivity (<a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>), percentage change in brachial artery diameter after release of transient occlusion (<a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>), and serum hs‐CRP (<a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). </p> <p>Secondary outcomes included lipid profile and serum insulin levels (all studies), serum testosterone (<a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>), change in HOMA‐IR (<a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>), hirsutism score (<a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>), and hs‐CRP (<a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>). </p> <p>Most studies also reported outcomes that were not prespecified. <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>, <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> and <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> reported menstrual regularity. <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> and <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> also reported serum levels of hs‐CRP, insulin, and advanced glycated end‐products; and endothelial function. In addition, <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported acne and hirsutism, and <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> reported hirsutism. <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> reported serum 25‐hydroxyvitamin D levels. </p> <p>No studies mentioned the accuracy of analytical methods used to detect very low levels of serum testosterone and hs‐CRP. However, the corresponding author of <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> informed us that the functional sensitivity for the testosterone assay was 0.14 ng/mL (95% CI 0.11 to 0.17), and the analytical sensitivity was 0.08 ng/mL for the instrument ARCHITECT. This study fulfilled the criteria with no significant effects of other interferences such as cross‐reaction with aldosterone or other steroidal hormones. </p> <p>No studies described any postintervention follow‐up.</p> <p>See the <a href="./references#CD008565-sec-0211" title="">Characteristics of included studies</a> table, <a href="#CD008565-tbl-0007">Table 2</a>, and <a href="#CD008565-tbl-0008">Table 3</a> for baseline characteristics of participants. </p> <div class="table" id="CD008565-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Attrition table</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Screened, n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Treatment groups</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised, n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Completed, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reasons for attrition</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: simvastatin + metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months: 37 (84%)</p> <p>6 months: 36 (82%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Loss of contact due to changes in telephone, mail, or residence address; or immigration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: simvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months: 41 (85%)</p> <p>6 months: 28 (58%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months: 36 (77%)</p> <p>6 months: 33 (70%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months: 114 (82%)</p> <p>6 months: 97 (70%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: simvastatin + OCP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: OCP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (100%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: simvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (92%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Loss to follow‐up, non‐compliance with study protocol, refusal to continue participating in study, not using allocated treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: flutamide + OCP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 (92%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: atorvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T2DM (n = 1), non‐adherence (n = 2), arthralgia (n = 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menorrhagia with anaemia (n = 1), T2DM (n = 2), non‐adherence (n = 2), myalgia (n = 1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: atorvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Use of OCP during follow‐up period</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (90%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>40/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: atorvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Non‐compliance with statins regimen based on pill count</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (90%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37(93%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1295 (96.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>C: control; I: intervention; NA: not applicable; NR: not reported; OCP: oral contraceptive pill; T2DM: type 2 diabetes mellitus. </p> </div> </div> </section> </section> <section id="CD008565-sec-0051"> <h4 class="title">Excluded studies</h4> <p>In the previous version of this review, we excluded four studies (<a href="./references#CD008565-bbs2-0010" title="EconomouF , XyrafisX , ChristakouC , Diamanti-KandarakisE . The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond. Current Pharmaceutical Design2011;19(9):908-21. ">Economou 2011</a>; <a href="./references#CD008565-bbs2-0014" title="KayaC , CengizSD , BerkerB , DemirtasS , CesurM , ErdoganG . Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertility and Sterility2009;92(2):635-42. ">Kaya 2009</a>; <a href="./references#CD008565-bbs2-0015" title="KayaC , PabuccuR , CengizSD , DunderI . Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: a prospective, randomized study. Experimental and Clinical Endocrinology and Diabetes2010;118(3):161-6. ">Kaya 2010</a>; <a href="./references#CD008565-bbs2-0016" title="KazerooniT , Shojaei-BaghiniA , DehbashiS , AsadiN , GhaffarpasandF , KazeroonicY . Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertility and Sterility2010;94(6):2208-13. ">Kazerooni 2010</a>). </p> <p>In the current update, we excluded 14 studies after assessing full‐text articles. Two were RCTs examining the effect of statins in women with PCOS actively trying to conceive (<a href="./references#CD008565-bbs2-0021" title="PourmatroudE , JafariRM . Abstract no: O-11: Two protocols for pretreatment in women with polycystic ovary syndrome before intracytoplasmic sperm injection cycle; a prospective, randomized, clinical trial. In: Iranian Journal of Reproductive Medicine. Vol. 4 (6 Suppl 1). 2014:O-11. PourmatroudE , MohamadJafariR . Comparison of metformin and simvastatin administration in women with polycystic ovary syndrome before intracytoplasmic sperm injection cycle; a prospective, randomized, clinical trial. Human Reproduction2014;29 Suppl 1:i334 Abstract no: P-525. ">Pourmatroud 2014</a>; <a href="./references#CD008565-bbs2-0022" title="RashidiB , AbediaslJ , TehraninejadE , RahmanpourH , SillsES . Simvastatin effects on androgens, inflammatory mediators, and endogenous pituitary gonadotropins among patients with PCOS undergoing IVF: results from a prospective, randomized, placebo-controlled clinical trial. Journal of Investigative Medicine: Official Publication of The American Federation for Clinical Research2011;59(6):912-6. [PMID: 21527854]">Rashidi 2011</a>), four were non‐randomised (<a href="./references#CD008565-bbs2-0007" title="AkbariM , AlmasiA , NaderiZ , KouhpayezadehJ , PouraliR , HossinzadehZ . The effect of atorvastatin on the ovarian arterial blood flow and serum androgen level in PCOS patient. Biomedical and Pharmacology Journal2016;9(3):1041-8. ">Akbari 2016</a>; <a href="./references#CD008565-bbs2-0009" title="CelikO , AcbayO , CelikO , AcbayO . Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. Journal of Endocrinological Investigation2012;35(10):905-10. ">Celik 2012</a>; <a href="./references#CD008565-bbs2-0018" title="MalikM , TasnimN , MahmudG . Effect of metformin alone compared with metformin plus simvastatin on polycystic ovarian syndrome in Pakistani women. Journal of the College of Physicians and Surgeons – Pakistan2018;28(3):184-7. [PMID: 29544572]">Malik 2018</a>; <a href="./references#CD008565-bbs2-0024" title="YangB , SunZJ , ChenB , ZhangJ , ZhaoH , LiCW , et al. Statin ameliorates endothelial dysfunction and insulin resistance in Tibet women with polycystic ovary syndrome. European Review for Medical and Pharmacological Sciences2016;20(6):1185-91. [PMID: 27049276]">Yang 2016</a>), one was a review article (<a href="./references#CD008565-bbs2-0008" title="BanaszewskaB , SpaczynskiR , PawelczykL . Statins in the treatment of polycystic ovary syndrome. Ginekologia Polska2010;81(8):618-21. ">Banaszewska 2010</a>), one had the wrong study design (<a href="./references#CD008565-bbs2-0019" title="NavaliN , PourabolghasemS , FouladiRF , NikpourMA . Therapeutic effects of biguanide vs. statin in polycystic ovary syndrome: a randomized clinical trial. Pakistan Journal of Biological Sciences2011;14(11):658-63. [PMID: 22235508]">Navali 2011</a>), two were systematic reviews (<a href="./references#CD008565-bbs2-0011" title="GaoL , LiSC . Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. In: Value in Health. Vol. 15. 2012:A659-60. GaoL , ZhaoFL , LiSC . Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Experimental and Clinical Endocrinology &amp; Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association2012;120(6):367-75. [PMID: 22639397]">Gao 2012</a>; <a href="./references#CD008565-bbs2-0023" title="SunJ , YuanY , CaiR , SunH , ZhouY , WangP , et al. An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials. BMJ Open2015;5:e007280. ">Sun 2015</a>), and four were studies examining the role of interventions other than statins in women with PCOS (<a href="./references#CD008565-bbs2-0012" title="AwwadJ , AbbasHA , SkaffB , HarajleyS , GhazeeriG . Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome. Human Reproduction2014;29 Suppl 1:i340 Abstract no: P-539. GhazeeriG , AbbasHA , SkaffB , HarajlyS , AwwadJ . Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients. Journal of Endocrinological Investigation2015;38(6):643-51. ">Ghazeeri 2015</a>; <a href="./references#CD008565-bbs2-0013" title="IRCT20140525017827N8. Comparison of metabolic, endocrine, and clinical outcomes of treatment with simvastatin and metformin in women suffering from PCOS. en.irct.ir/trial/46990 (first received 10 April 2020). ">IRCT20140525017827N8</a>; <a href="./references#CD008565-bbs2-0017" title="KrysiakR , OkopienB . The effect of atorvastatin and atorvastatin-ezetimibe combination therapy on androgen production in hyperandrogenic women with elevated cholesterol levels. Experimental and Clinical Endocrinology &amp; Diabetes2015;123:75-9. KrysiakR , ZmudaW , OkopienB . The effect of ezetimibe on androgen production in hypercholesterolemic women with polycystic ovary syndrome. Cardiovascular Therapeutics2014;32:219-23. ">Krysiak 2015</a>; <a href="./references#CD008565-bbs2-0020" title="BanaszewskaB . Effects of simvastatin and micronized trans-resveratrol treatment on polycystic ovary syndrome (pcos) patients. clinicaltrials.gov/ct2/show/NCT02766803 (first received 10 May 2016). ">NCT02766803</a>). For details of each of these studies, please see the <a href="./references#CD008565-sec-0212" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD008565-sec-0052"> <h4 class="title">Studies awaiting classification</h4> <p>We listed eight studies as awaiting classification. Three were registered but not published. For one study, we were unable to retrieve the full text or find more information. For two, the published data were incomplete and the study authors did not respond to our request for more information. For the last two, we have contacted the study authors for confirmation of data. See the <a href="./references#CD008565-bbs1-0003" title="">Studies awaiting classification</a> table for details. </p> </section> </section> <section id="CD008565-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD008565-fig-0002">Figure 2</a> (risk of bias graph) and <a href="#CD008565-fig-0003">Figure 3</a> (risk of bias summary). </p> <div class="figure" id="CD008565-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008565-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008565-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008565-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008565-sec-0054"> <h4 class="title">Allocation</h4> <section id="CD008565-sec-0055"> <h5 class="title">Sequence generation</h5> <p>Four studies were at low risk of selection bias related to sequence generation because they used computerised methods or a random numbers table (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>; <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> and <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not clearly describe the method of generating random sequences (unclear risk of bias). </p> </section> <section id="CD008565-sec-0056"> <h5 class="title">Allocation concealment</h5> <p>Three studies were at low risk of selection bias related to allocation concealment (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>; <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>), and three studies were at unclear risk because they did not clearly describe the methods for concealing allocation (<a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). </p> </section> </section> <section id="CD008565-sec-0057"> <h4 class="title">Blinding</h4> <p>Three studies were at high risk of performance bias (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>), and three were at low risk (<a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>; <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> and <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> were at low risk of detection bias because they were described as double‐blind, whereas <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> and <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> were at high risk because they were open‐label studies. The remaining two studies were at unclear risk of detection bias: <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> was a single‐blind study, and the method of blinding was unclear in <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>. No study publication described checking of blinding conditions or any precautions taken when blinding lipid profile data in the follow‐up and endpoint evaluation. The corresponding author of <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> informed us that the investigators maintained blinding at the two measurement time points (baseline and endpoint). </p> </section> <section id="CD008565-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>Risk of attrition bias was low in three studies, which had no or few dropouts (<a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>) or used ITT analysis (<a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>). The risk of attrition bias was high in three studies, which had attrition rates of 8.1% (<a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>), 16.9% (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>), and 29% (<a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>), and used per‐protocol analysis. For details on attrition rates in each study, see <a href="#CD008565-tbl-0008">Table 3</a>. </p> </section> <section id="CD008565-sec-0059"> <h4 class="title">Selective reporting</h4> <p>There was a high risk of reporting bias in five studies (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>; <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). Three studies reported clinical outcomes that were not prespecified in the methods section of the full‐text articles (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report some outcomes prespecified in the study register (e.g. there were no reported follow‐up data on insulin resistance). <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> was at low risk of selective reporting because all outcomes mentioned in the methods section were reported in the results, and there were no additional outcomes. </p> </section> <section id="CD008565-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> was at high risk of other bias due to a significant difference in baseline BMI between the two groups. <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> also had significant differences in the baseline characteristics of glucose, insulin, and testosterone and was assessed as high risk. <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported significant baseline differences between the groups in HDL and follicle stimulating hormone, and <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> reported differences in waist circumference, while BMI was comparable. The potential for bias was unclear in these two studies. <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> and <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> appeared to be at low risk of other potential sources of bias. </p> </section> </section> <section id="CD008565-sec-0061"> <h3 class="title" id="CD008565-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD008565-tbl-0001"><b>Summary of findings 1</b> Statin compared to placebo for women with polycystic ovary syndrome not actively trying to conceive</a>; <a href="./full#CD008565-tbl-0002"><b>Summary of findings 2</b> Statin plus metformin compared to metformin alone for women with polycystic ovary syndrome not actively trying to conceive</a>; <a href="./full#CD008565-tbl-0003"><b>Summary of findings 3</b> Statin plus oral contraceptive pill compared to oral contraceptive pill alone for women with polycystic ovary syndrome not actively trying to conceive</a>; <a href="./full#CD008565-tbl-0004"><b>Summary of findings 4</b> Statin compared to metformin for women with polycystic ovary syndrome not actively trying to conceive</a>; <a href="./full#CD008565-tbl-0005"><b>Summary of findings 5</b> Statin compared to oral contraceptive pill plus flutamide for women with polycystic ovary syndrome not actively trying to conceive</a> </p> <section id="CD008565-sec-0062"> <h4 class="title">1. Statin versus placebo</h4> <p>Three studies evaluated statins versus placebo (<a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>, <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>, <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). They compared the effects of statins and metformin after six weeks (<a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>), three months (<a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>), and six months of treatment (<a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>). See <a href="./full#CD008565-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD008565-sec-0063"> <h5 class="title">Primary outcomes</h5> <section id="CD008565-sec-0064"> <h6 class="title">1.1 Resumption of menstrual regularity</h6> <p>Only <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> reported resumption of menstrual regularity (as length of menstrual cycle in days). We are uncertain if statins compared with placebo shorten mean length of menstrual cycle (MD −2.00 days, 95% CI −24.86 to 20.86; 37 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD008565-sec-0065"> <h6 class="title">1.2 Resumption of spontaneous ovulation</h6> <p>No studies reported resumption of spontaneous ovulation.</p> </section> </section> <section id="CD008565-sec-0066"> <h5 class="title">Secondary outcomes</h5> <section id="CD008565-sec-0067"> <h6 class="title">1.3 Improvement in body composition</h6> <section id="CD008565-sec-0068"> <p><b>1.3.1 Body mass index</b></p> <p>All three studies provided analysable data on BMI. We are uncertain if statins reduce BMI compared with placebo (MD 1.06 kg/m<sup>2</sup>, 95% CI −1.87 to 3.99; I<sup>2</sup> = 3%; 3 RCTs, 85 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0005" title="">Analysis 1.2</a>). We downgraded the certainty of the evidence twice for imprecision and once for risk of bias. </p> </section> <section id="CD008565-sec-0069"> <p><b>1.3.2 Waist circumference</b></p> <p>Only <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> reported waist circumference. We are uncertain of the effect of statins on waist circumference compared with placebo (MD 0.20 cm, 95% CI −5.76 to 6.16; 37 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0006" title="">Analysis 1.3</a>). We downgraded the certainty of the evidence twice for imprecision and once for risk of bias. </p> </section> <section id="CD008565-sec-0070"> <p><b>1.3.3 Waist‐hip ratio</b></p> <p>Only <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> reported WHR. We are uncertain of the effect of statins on WHR compared with placebo (MD 0.03, 95% CI −0.02 to 0.08; 28 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0007" title="">Analysis 1.4</a>). We downgraded the certainty of the evidence twice for imprecision and once for risk of bias. </p> </section> </section> <section id="CD008565-sec-0071"> <h6 class="title">1.4 Improvement in hirsutism</h6> <p>No studies reported hirsutism.</p> </section> <section id="CD008565-sec-0072"> <h6 class="title">1.5 Improvement in acne severity</h6> <p>No studies reported acne severity.</p> </section> <section id="CD008565-sec-0073"> <h6 class="title">1.6 Improvement in testosterone level</h6> <p>All three studies reported testosterone level. We are uncertain if statins compared with placebo reduce testosterone levels after six weeks (MD 0.06 nmol/L, 95% CI −0.72 to 0.84; 1 RCT, 20 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0008" title="">Analysis 1.5</a>), 3 months (MD −0.53 nmol/L, 95% CI −1.61 to 0.54; 2 RCTs, 64 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0008" title="">Analysis 1.5</a>), or six months (MD 0.10 nmol/L, 95% CI −0.43 to 0.63; 1 RCT, 28 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD008565-sec-0074"> <h6 class="title">1.7 Improvement in lipid profile</h6> <section id="CD008565-sec-0075"> <p><b>1.7.1 Total cholesterol</b></p> <p>All three studies reported total cholesterol. Compared with placebo, statins may reduce total cholesterol (MD −1.31 mmol/L, 95% CI −1.64 to −0.97; I<sup>2</sup> = 0%; 3 RCTs, 85 participants; low‐certainty evidence; <a href="./references#CD008565-fig-0009" title="">Analysis 1.6</a>). We downgraded the certainty of the evidence once each for imprecision and risk of bias. </p> </section> <section id="CD008565-sec-0076"> <p><b>1.7.2 Low‐density lipoprotein cholesterol</b></p> <p>All three studies reported LDL cholesterol. Compared with placebo, statins may reduce LDL cholesterol (MD −1.10 mmol/L, 95% CI −1.38 to −0.81; I<sup>2</sup> = 0%; 3 RCTs, 85 participants; low‐certainty evidence; <a href="./references#CD008565-fig-0010" title="">Analysis 1.7</a>). We downgraded the certainty of the evidence once each for imprecision and risk of bias. </p> </section> <section id="CD008565-sec-0077"> <p><b>1.7.3 High‐density lipoprotein cholesterol</b></p> <p>All three studies reported HDL cholesterol. Compared with placebo, statins may have little or no effect on HDL cholesterol (MD 0.00 mmol/L, 95% CI −0.15 to 0.15; I<sup>2</sup> = 0%; 3 RCTs, 85 participants; low‐certainty evidence; <a href="./references#CD008565-fig-0011" title="">Analysis 1.8</a>). We downgraded the certainty of the evidence once each for imprecision and risk of bias. </p> </section> <section id="CD008565-sec-0078"> <p><b>1.7.4 Triglycerides</b></p> <p>All three studies reported triglycerides. Statins may lower triglyceride levels compared with placebo (MD −0.39 mmol/L, 95% CI −0.60 to −0.18; I<sup>2</sup> = 37%; 3 RCTs, 85 participants; low‐certainty evidence; <a href="./references#CD008565-fig-0012" title="">Analysis 1.9</a>). We downgraded the certainty of the evidence once each for imprecision and risk of bias. </p> </section> </section> <section id="CD008565-sec-0079"> <h6 class="title">1.8 Improvement in high‐sensitivity C‐reactive protein</h6> <p>All the three studies provided analysable data on hs‐CRP. Compared with placebo, we are uncertain if statins reduce hs‐CRP levels (MD −7.76 nmol/L, 95% CI −20.99 to 5.48; I<sup>2</sup> = 0%; 3 RCTs, 84 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0013" title="">Analysis 1.10</a>). We downgraded the certainty of the evidence once each for imprecision and risk of bias. </p> </section> <section id="CD008565-sec-0080"> <h6 class="title">1.9 Improvement in insulin sensitivity</h6> <section id="CD008565-sec-0081"> <p><b>1.9.1 Fasting insulin</b></p> <p>All three studies provided analysable data for fasting insulin. We are uncertain if statins improve fasting insulin levels compared with placebo (MD −0.31 µIU/mL, 95% CI −5.18 to 4.57) I<sup>2</sup> = 55%; 3 RCTs, 85 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0014" title="">Analysis 1.11</a>). We downgraded the certainty of the evidence twice for imprecision and once for risk of bias. </p> </section> <section id="CD008565-sec-0082"> <p><b>1.9.2 Glucose/insulin ratio</b></p> <p>No studies reported glucose/insulin ratio.</p> </section> <section id="CD008565-sec-0083"> <p><b>1.9.3 Homeostatic model assessment for insulin resistance</b></p> <p>Only <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> reported HOMA‐IR. We are uncertain if statins reduce HOMA‐IR compared with placebo (MD −1.10, 95% CI −2.35 to 0.15; 37 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0015" title="">Analysis 1.12</a>). We downgraded the certainty of the evidence twice for imprecision and once for risk of bias. </p> </section> <section id="CD008565-sec-0084"> <p><b>1.9.4 Standard measures from euglycaemic clamps or intravenous glucose tolerance tests</b></p> <p><a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> reported intravenous glucose tolerance test (IVGTT) insulin sensitivity. Statins may reduce insulin sensitivity measured by IVGTT compared with placebo (MD −3.50, 95% CI −6.06 to −0.94; 28 participants; low‐certainty evidence; <a href="./references#CD008565-fig-0016" title="">Analysis 1.13</a>). We downgraded the certainty of the evidence twice for imprecision and once for risk of bias. </p> </section> </section> <section id="CD008565-sec-0085"> <h6 class="title">1.10 Adverse effects</h6> <p>In <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>, one woman in the statin group stopped treatment because of arthralgia and one woman in the placebo group withdrew because of myalgia. <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> stated that no adverse events occurred in either the placebo or the atorvastatin group. <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> did not report adverse events. </p> </section> </section> </section> <section id="CD008565-sec-0086"> <h4 class="title">2. Statin plus metformin versus metformin</h4> <p>One study evaluated statin plus metformin versus metformin and compared the effects of statins and metformin after six months (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>). See <a href="./full#CD008565-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD008565-sec-0087"> <h5 class="title">Primary outcomes</h5> <section id="CD008565-sec-0088"> <h6 class="title">2.1 Resumption of menstrual regularity</h6> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported resumption of menstrual regularity as number of spontaneous menses per six months. We are uncertain if statins plus metformin improves resumption of menstrual regularity compared with metformin alone (MD 0.60 menses, 95% CI 0.08 to 1.12; 69 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0017" title="">Analysis 2.1</a>). </p> </section> <section id="CD008565-sec-0089"> <h6 class="title">2.2 Resumption of spontaneous ovulation</h6> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> did not report resumption of spontaneous ovulation. </p> </section> </section> <section id="CD008565-sec-0090"> <h5 class="title">Secondary outcomes</h5> <section id="CD008565-sec-0091"> <h6 class="title">2.3 Improvement in body composition</h6> <section id="CD008565-sec-0092"> <p><b>2.3.1 Body mass index</b></p> <p>We are uncertain if statins plus metformin reduces BMI compared with metformin alone (MD −0.42 kg/m<sup>2</sup>, 95% CI −1.25 to 0.41; 69 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0018" title="">Analysis 2.2</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0093"> <p><b>2.3.2 Waist circumference</b></p> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> did not report waist circumference. </p> </section> <section id="CD008565-sec-0094"> <p><b>2.3.3 Waist‐hip ratio</b></p> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> did not report WHR. </p> </section> </section> <section id="CD008565-sec-0095"> <h6 class="title">2.4 Improvement in hirsutism</h6> <p>We are uncertain if statins plus metformin compared with metformin alone improves hirsutism measured using the Ferriman‐Gallwey score (MD −0.16, 95% CI −0.91 to 0.59; 69 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0019" title="">Analysis 2.3</a>). </p> </section> <section id="CD008565-sec-0096"> <h6 class="title">2.5 Improvement in acne severity</h6> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported acne severity using a four‐point clinical scale (0 = no acne; 1 = minor acne on the face only; 2 = moderate acne on the face only; 3 = severe acne on the face and back or chest). We are uncertain if statins plus metformin compared with metformin alone improves acne severity (MD −0.31, 95% CI −0.67 to 0.05; 69 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0020" title="">Analysis 2.4</a>). </p> </section> <section id="CD008565-sec-0097"> <h6 class="title">2.6 Improvement in testosterone level</h6> <p>We are uncertain if statins plus metformin improves serum testosterone compared with metformin alone (MD −0.03 nmol/L, 95% CI −0.37 to 0.31; 69 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0021" title="">Analysis 2.5</a>). </p> </section> <section id="CD008565-sec-0098"> <h6 class="title">2.7 Improvement in lipid profile</h6> <section id="CD008565-sec-0099"> <p><b>2.7.1 Total cholesterol</b></p> <p>It is unclear if statins plus metformin reduces total cholesterol compared with metformin alone, because the evidence is of very low certainty (MD −0.97 mmol/L, 95% CI −1.34 to −0.60; 69 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0022" title="">Analysis 2.6</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0100"> <p><b>2.7.2 Low‐density lipoprotein cholesterol</b></p> <p>It is unclear if statins plus metformin compared with metformin alone reduces LDL cholesterol, because the evidence is of very low certainty (MD −0.89 mmol/L, 95% CI −1.20 to −0.58, very low‐certainty evidence; <a href="./references#CD008565-fig-0023" title="">Analysis 2.7</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0101"> <p><b>2.7.3 High‐density lipoprotein cholesterol (mmol/L)</b></p> <p>It is unclear if statins plus metformin improves HDL levels compared with metformin alone (MD −0.03 mmol/L, 95% CI −0.17 to 0.11; 69 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0024" title="">Analysis 2.8</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0102"> <p><b>2.7.4 Triglycerides (mmol/L)</b></p> <p>It is unclear if statins plus metformin compared with metformin alone reduce triglycerides, because the evidence is of very low certainty (MD −0.29 mmol/L, 95% CI −0.51 to −0.07; 69 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0025" title="">Analysis 2.9</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> </section> <section id="CD008565-sec-0103"> <h6 class="title">2.8 Improvement in high‐sensitivity C‐reactive protein</h6> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> did not report hs‐CRP. </p> </section> <section id="CD008565-sec-0104"> <h6 class="title">2.9 Improvement in insulin sensitivity</h6> <section id="CD008565-sec-0105"> <p><b>2.9.1 Fasting insulin</b></p> <p>It is unclear if statins plus metformin compared with metformin alone decreases fasting insulin levels, because the evidence is of very low certainty (MD −2.45 µIU/mL, 95% CI −4.91 to 0.01; 69 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0026" title="">Analysis 2.10</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0106"> <p><b>2.9.2 Glucose/insulin ratio</b></p> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> did not report glutose/insulin ratio. </p> </section> <section id="CD008565-sec-0107"> <p><b>2.9.3 Homeostatic model assessment for insulin resistance</b></p> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> did not report HOMA‐IR. </p> </section> <section id="CD008565-sec-0108"> <p><b>2.9.4 Standard measures from euglycaemic clamps or intravenous glucose tolerance tests</b></p> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> did not report any standard measures from euglycaemic clamps or intravenous glucose tolerance tests. </p> </section> </section> <section id="CD008565-sec-0109"> <h6 class="title">2.10 Adverse effects</h6> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported that no significant adverse events occurred. </p> </section> </section> </section> <section id="CD008565-sec-0110"> <h4 class="title">3. Statin plus oral contraceptive pill versus oral contraceptive pill alone</h4> <p>One study evaluated statin plus OCP versus OCP alone (<a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>). The reported treatment duration was 12 weeks. See <a href="./full#CD008565-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD008565-sec-0111"> <h5 class="title">Primary outcomes</h5> <section id="CD008565-sec-0112"> <h6 class="title">3.1 Resumption of menstrual regularity</h6> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report resumption of menstrual regularity. </p> </section> <section id="CD008565-sec-0113"> <h6 class="title">3.2 Resumption of spontaneous ovulation</h6> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report resumption of spontaneous ovulation. </p> </section> </section> <section id="CD008565-sec-0114"> <h5 class="title">Secondary outcomes</h5> <section id="CD008565-sec-0115"> <h6 class="title">3.3 Improvement in body composition</h6> <section id="CD008565-sec-0116"> <p><b>3.3.1 Body mass index</b></p> <p>It is unclear if statins plus OCP compared with OCP alone improves BMI (MD 0.05 kg/m<sup>2</sup>, 95% CI −0.41 to 0.51; 48 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0027" title="">Analysis 3.1</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0117"> <p><b>3.3.2 Waist circumference</b></p> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report waist circumference. </p> </section> <section id="CD008565-sec-0118"> <p><b>3.3.3 Waist‐hip ratio</b></p> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report WHR. </p> </section> </section> <section id="CD008565-sec-0119"> <h6 class="title">3.4 Improvement in hirsutism</h6> <p>We are uncertain if statins plus OCP compared with OCP alone improves hirsutism measured using the Ferriman‐Gallwey score (MD −0.12, 95% CI −0.41 to 0.17; 48 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0028" title="">Analysis 3.2</a>). </p> </section> <section id="CD008565-sec-0120"> <h6 class="title">3.5 Improvement in acne severity</h6> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report acne severity. </p> </section> <section id="CD008565-sec-0121"> <h6 class="title">3.6 Improvement in testosterone level</h6> <p>It is unclear if statins plus OCP compared with OCP alone reduces testosterone levels, because the certainty of the evidence is very low (MD −0.82 nmol/L, 95% CI −1.38 to −0.26; 48 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0029" title="">Analysis 3.3</a>). </p> </section> <section id="CD008565-sec-0122"> <h6 class="title">3.7 Improvement in lipid profile</h6> <section id="CD008565-sec-0123"> <p><b>3.7.1 Total cholesterol</b></p> <p>It is unclear if statins plus OCP compared with OCP alone decreases total cholesterol levels, because the certainty of the evidence is very low (MD −0.93 mmol/L, 95% CI −1.33 to −0.53; 48 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0030" title="">Analysis 3.4</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0124"> <p><b>3.7.2 Low‐density lipoprotein cholesterol</b></p> <p>It is unclear if statins plus OCP compared with OCP alone decreases LDL cholesterol, because the certainty of the evidence is very low (MD −0.74 mmol/L, 95% CI −1.14 to −0.34; 48 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0031" title="">Analysis 3.5</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0125"> <p><b>3.7.3 High‐density lipoprotein cholesterol</b></p> <p>We are uncertain if statins plus OCP compared with OCP alone increases HDL cholesterol (MD −0.06 mmol/L, 95% CI −0.22 to 0.10; 48 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0032" title="">Analysis 3.6</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0126"> <p><b>3.7.4 Triglycerides</b></p> <p>We are uncertain if statins plus OCP compared with OCP alone decreases triglycerides, because the certainty of the evidence is very low (MD −0.18 mmol/L, 95% CI −0.41 to 0.05; 48 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0033" title="">Analysis 3.7</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> </section> <section id="CD008565-sec-0127"> <h6 class="title">3.8 Improvement in high‐sensitivity C‐reactive protein</h6> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report hs‐CRP. </p> </section> <section id="CD008565-sec-0128"> <h6 class="title">3.9 Improvement in insulin sensitivity</h6> <section id="CD008565-sec-0129"> <p><b>3.9.1 Fasting insulin</b></p> <p>We are uncertain if statins plus OCP compared with OCP alone improves fasting insulin (MD 0.60 µIU/mL, 95% CI −2.15 to 3.35; 48 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0034" title="">Analysis 3.8</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0130"> <p><b>3.9.2 Glucose/insulin ratio</b></p> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report glucose/insulin ratio. </p> </section> <section id="CD008565-sec-0131"> <p><b>3.9.3 Homeostatic model assessment for insulin resistance</b></p> <p>We are uncertain if statins plus OCP compared with OCP alone reduces HOMA‐IR (MD −1.16, 95% CI −3.19 to 0.87; 48 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0035" title="">Analysis 3.9</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0132"> <p><b>3.9.4 Standard measures from euglycaemic clamps or intravenous glucose tolerance tests</b></p> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report any standard measures from euglycaemic clamps or intravenous glucose tolerance tests. </p> </section> </section> <section id="CD008565-sec-0133"> <h6 class="title">3.10 Adverse effects</h6> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> reported that no women experienced significant side effects, and all women completed the 12‐week treatment course. </p> </section> </section> </section> <section id="CD008565-sec-0134"> <h4 class="title">4. Statin versus metformin</h4> <p>Two studies compared the effects of statins with the effects of metformin after six months of treatment (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>). See <a href="./full#CD008565-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD008565-sec-0135"> <h5 class="title">Primary outcomes</h5> <section id="CD008565-sec-0136"> <h6 class="title">4.1 Resumption of menstrual regularity</h6> <p>Only <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported resumption of menstrual regularity (as number of spontaneous menses per six months). We are uncertain if statins improve menstrual regularity compared with metformin (MD 0.50 menses, 95% CI −0.05 to 1.05; 61 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0036" title="">Analysis 4.1</a>). </p> </section> <section id="CD008565-sec-0137"> <h6 class="title">4.2 Resumption of spontaneous ovulation</h6> <p>No studies reported resumption of spontaneous ovulation.</p> </section> </section> <section id="CD008565-sec-0138"> <h5 class="title">Secondary outcomes</h5> <section id="CD008565-sec-0139"> <h6 class="title">4.3 Improvement in body composition</h6> <section id="CD008565-sec-0140"> <p><b>4.3.1 Body mass index</b></p> <p>We are uncertain if statins improve BMI compared with metformin (MD −0.14 kg/m<sup>2</sup>, 95% CI −1.53 to 1.25; I<sup>2</sup> = 98%; 2 RCTs, 129 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0037" title="">Analysis 4.2</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0141"> <p><b>4.3.2 Waist circumference</b></p> <p>Only <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> reported wait circumference. It is unclear if statins compared with metformin decrease waist circumference, because the certainty of the evidence is very low (MD −1.64 cm, 95% CI −2.24 to −1.04; 68 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0038" title="">Analysis 4.3</a>). We downgraded the certainty of the evidence one level each for risk of bias concerns, imprecision, and indirectness. </p> </section> <section id="CD008565-sec-0142"> <p><b>4.3.3 Waist‐hip‐ratio</b></p> <p>No studies reported WHR.</p> </section> </section> <section id="CD008565-sec-0143"> <h6 class="title">4.4 Improvement in hirsutism</h6> <p>Only <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported hirsutism. We are uncertain if statins compared with metformin reduce hirsutism measured using the Ferriman‐Gallwey score (MD −0.26, 95% CI −0.97 to 0.45; 61 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0039" title="">Analysis 4.4</a>). </p> </section> <section id="CD008565-sec-0144"> <h6 class="title">4.5 Improvement in acne severity</h6> <p>Only <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported acne severity, using a four‐point clinical scale (0 = no acne; 1 = minor acne on the face only; 2 = moderate acne on the face only; 3 = severe acne on the face and back or chest). We are uncertain if statins reduce acne compared with metformin (MD −0.18, 95% CI −0.53 to 0.17; 61 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0040" title="">Analysis 4.5</a>). </p> </section> <section id="CD008565-sec-0145"> <h6 class="title">4.6 Improvement in testosterone level</h6> <p>Only <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported testosterone levels. We are uncertain if statins decrease serum testosterone compared with metformin (MD −0.24 nmol/L, 95% CI −0.58 to 0.10; 61 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0041" title="">Analysis 4.6</a>). </p> </section> <section id="CD008565-sec-0146"> <h6 class="title">4.7 Improvement in lipid profile</h6> <section id="CD008565-sec-0147"> <p><b>4.7.1 Total cholesterol</b></p> <p>Only <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported total cholesterol. Compared with metformin, statins may reduce total cholesterol (MD −0.99 mmol/L, 95% CI −1.38 to −0.60; 1 RCT, 61 participants; low‐certainty evidence; <a href="./references#CD008565-fig-0042" title="">Analysis 4.7</a>). We downgraded the certainty of the evidence one level each for imprecision and risk of bias. </p> </section> <section id="CD008565-sec-0148"> <p><b>4.7.2 Low‐density lipoprotein cholesterol</b></p> <p>Only <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported LDL cholesterol. Compared with metformin, statins may reduce LDL cholesterol (MD −0.91 mmol/L, 95% CI −1.24 to −0.58; 1 RCT, 61 participants; low‐certainty evidence; <a href="./references#CD008565-fig-0043" title="">Analysis 4.8</a>). We downgraded the certainty of the evidence one level each for imprecision and risk of bias. </p> </section> <section id="CD008565-sec-0149"> <p><b>4.7.3 High‐density lipoprotein cholesterol</b></p> <p>Both studies reported HDL cholesterol. Compared with metformin, statins may have little or no effect on HDL cholesterol (MD 0.00 mmol/L, 95% CI −0.02 to 0.02; I<sup>2</sup> = 0%; 2 RCTs, 129 participants; low‐certainty evidence; <a href="./references#CD008565-fig-0044" title="">Analysis 4.9</a>). We downgraded the certainty of the evidence one level each for imprecision and risk of bias. </p> </section> <section id="CD008565-sec-0150"> <p><b>4.7.4 Triglycerides</b></p> <p>Both studies reported triglycerides. Compared with metformin, statins may reduce triglycerides (MD −0.19 mmol/L, 95% CI −0.29 to −0.10; I<sup>2</sup> = 0%; 2 RCTs, 129 participants; low‐certainty evidence; <a href="./references#CD008565-fig-0045" title="">Analysis 4.10</a>). We downgraded the certainty of the evidence one level each for imprecision and risk of bias. </p> </section> </section> <section id="CD008565-sec-0151"> <h6 class="title">4.8 Improvement in high‐sensitivity C‐reactive protein</h6> <p>Only <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> reported hs‐CRP. It is unclear if statins compared with metformin reduce hs‐CRP, because the certainty of the evidence is very low (MD −1.62 nmol/L, 95% CI −2.60 to −0.64; 68 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0046" title="">Analysis 4.11</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0152"> <h6 class="title">4.9 Improvement in insulin sensitivity</h6> <section id="CD008565-sec-0153"> <p><b>4.9.1 Fasting insulin</b></p> <p>Only <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported fasting insulin. We are uncertain if statins compared with metformin have an effect on fasting insulin levels (MD −1.01 µIU/mL, 95% CI −3.27 to 1.25; 61 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0047" title="">Analysis 4.12</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0154"> <p><b>4.9.2 Glucose/insulin ratio</b></p> <p>No studies reported glucose/insulin ratio.</p> </section> <section id="CD008565-sec-0155"> <p><b>4.9.3 Homeostatic model assessment for insulin resistance</b></p> <p>No studies reported HOMA‐IR.</p> </section> <section id="CD008565-sec-0156"> <p><b>4.9.4 Standard measures from euglycaemic clamps or intravenous glucose tolerance tests</b></p> <p>No studies reported any standard measures from euglycaemic clamps or intravenous glucose tolerance tests. </p> </section> </section> <section id="CD008565-sec-0157"> <h6 class="title">4.10 Adverse effects</h6> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported that six women using metformin experienced transient gastrointestinal side effects including diarrhoea; however, these women did not discontinue treatment. <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> reported that no participants experienced significant side effects. </p> </section> </section> </section> <section id="CD008565-sec-0158"> <h4 class="title"><i>5.</i> Statin versus oral contraceptive pill plus flutamide </h4> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> compared the effects of statin versus the effects of OCP in combination with flutamide. See <a href="./full#CD008565-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD008565-sec-0159"> <h5 class="title">Primary outcomes</h5> <section id="CD008565-sec-0160"> <h6 class="title">5.1 Resumption of menstrual regularity</h6> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report resumption of menstrual regularity. </p> </section> <section id="CD008565-sec-0161"> <h6 class="title">5.2 Resumption of spontaneous ovulation</h6> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report resumption of spontaneous ovulation. </p> </section> </section> <section id="CD008565-sec-0162"> <h5 class="title">Secondary outcomes</h5> <section id="CD008565-sec-0163"> <h6 class="title">5.3 Improvement in body composition</h6> <section id="CD008565-sec-0164"> <p><b>5.3.1 Body mass index</b></p> <p>We are uncertain if statins compared with OCP plus flutamide improve BMI, because the certainty of the evidence is very low (MD −1.05 kg/m<sup>2</sup>, 95% CI −1.23 to −0.87; 68 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0048" title="">Analysis 5.1</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0165"> <p><b>5.3.2 Waist circumference</b></p> <p>It is unclear if statins improve waist circumference compared with OCP plus flutamide, because the certainty of the evidence is very low (MD −1.91 cm, 95% CI −2.49 to −1.33; 68 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0049" title="">Analysis 5.2</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0166"> <p><b>5.3.3 Waist‐hip‐ratio</b></p> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report WHR. </p> </section> </section> <section id="CD008565-sec-0167"> <h6 class="title">5.4 Improvement in hirsutism</h6> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report hirsutism. </p> </section> <section id="CD008565-sec-0168"> <h6 class="title">5.5 Improvement in acne severity</h6> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report acne severity. </p> </section> <section id="CD008565-sec-0169"> <h6 class="title">5.6 Improvement in testosterone levels</h6> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report testosterone levels. </p> </section> <section id="CD008565-sec-0170"> <h6 class="title">5.7 Improvement in lipid profile</h6> <section id="CD008565-sec-0171"> <p><b>5.7.1 Total cholesterol</b></p> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report total cholesterol. </p> </section> <section id="CD008565-sec-0172"> <p><b>5.7.2 Low‐density lipoprotein cholesterol</b></p> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report LDL cholesterol. </p> </section> <section id="CD008565-sec-0173"> <p><b>5.7.3 High‐density lipoprotein cholesterol</b></p> <p>We are uncertain if statins improve HDL levels compared with OCP plus flutamide (MD 0.00 mmol/L, 95% CI −0.02 to 0.02; 68 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0050" title="">Analysis 5.3</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0174"> <p><b>5.7.4 Triglycerides</b></p> <p>It is unclear if statins compared with OCP plus flutamide improve triglyceride levels, because the certainty of the evidence is very low (MD −0.14 mmol/L, 95% CI −0.24 to −0.04; 68 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0051" title="">Analysis 5.4</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> </section> <section id="CD008565-sec-0175"> <h6 class="title">5.8 Improvement in high‐sensitivity C‐reactive protein</h6> <p>We are uncertain if statins reduce hs‐CRP compared with OCP plus flutamide (MD 0.48 nmol/L, 95% CI −0.93 to 1.89; 68 participants; very low‐certainty evidence; <a href="./references#CD008565-fig-0052" title="">Analysis 5.5</a>). We downgraded the certainty of the evidence twice for imprecision and twice for risk of bias. </p> </section> <section id="CD008565-sec-0176"> <h6 class="title">5.9 Improvement in insulin sensitivity</h6> <section id="CD008565-sec-0177"> <p><b>5.9.1 Fasting insulin</b></p> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report fasting insulin. </p> </section> <section id="CD008565-sec-0178"> <p><b>5.9.2 Glucose/insulin ratio</b></p> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report glucose/insulin ratio. </p> </section> <section id="CD008565-sec-0179"> <p><b>5.9.3 Homeostatic model assessment for insulin resistance</b></p> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report HOMA‐IR. </p> </section> <section id="CD008565-sec-0180"> <p><b>5.9.4 Standard measures from euglycaemic clamps or intravenous glucose tolerance tests</b></p> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report any standard measures from euglycaemic clamps or intravenous glucose tolerance tests. </p> </section> </section> <section id="CD008565-sec-0181"> <h6 class="title">5.10 Adverse effects</h6> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> reported that no women experienced any significant side effects. </p> </section> </section> </section> <section id="CD008565-sec-0182"> <h4 class="title">Sensitivity analysis</h4> <p>We were unable to perform any of the prespecified sensitivity analyses due to insufficient data. </p> </section> <section id="CD008565-sec-0183"> <h4 class="title">Assessment of publication bias</h4> <p>We could not assess publication bias due to insufficient data.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008565-sec-0184" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008565-sec-0184"></div> <section id="CD008565-sec-0185"> <h3 class="title" id="CD008565-sec-0185">Summary of main results</h3> <p>This review aimed to generate evidence on the efficacy and safety of statins for the treatment of hyperandrogenism and adverse metabolic parameters of PCOS in women who were not actively attempting to conceive. We included six studies that evaluated the effect of statins (alone or in combination with OCP or metformin) on different clinical outcomes. The main reported outcomes were resumption of menstrual regularity, improvement in hirsutism, and improvement in acne severity. The certainty of the evidence was very low for all our main outcomes with analysable data. No studies reported resumption of spontaneous ovulation. In terms of biochemical parameters, the studies evaluating statins versus placebo or statins plus metformin versus metformin showed no significant reduction in serum testosterone concentration (a surrogate indicator of hirsutism or acne in most studies). <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> found that statins plus OCP compared with OCP alone decreased testosterone levels but did not improve hirsutism; however, the certainty of the evidence was very low, so the results should be interpreted with caution. As expected, we found that statins compared with placebo may reduce total cholesterol, LDL cholesterol, and triglyceride levels, which are the surrogate markers for cardiovascular outcomes. However, we found no evidence of effect for statins (alone or in combination with OCP or metformin) on serum HDL concentration. We also found no evidence of an effect of statin use (alone or combination with OCP or metformin) on serum fasting insulin concentration, hs‐CRP, or HOMA‐IR. This suggests that statins may have limited efficacy for treating hyperinsulinaemia or metabolic syndrome in women with PCOS. There was very limited evidence on the effect of statins on body composition; we found very low‐certainty evidence from different studies of no effect on waist circumference and BMI. </p> <p>Two studies examined the efficacy and safety of statins versus metformin (<a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>; <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>). Compared with metformin, statin monotherapy may reduce total cholesterol, LDL cholesterol, triglycerides, and hs‐CRP. There was no evidence of a difference in the effect of statins compared with metformin on testosterone levels, acne severity, hirsutism, or HDL cholesterol. <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> found that statins had a slight beneficial effect on resumption of menstrual regularity, and <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> found that statin monotherapy improved waist circumference, but the certainty of the evidence was very low for both outcomes. Most results from these two studies were consistent, though not for BMI. Both studies used the same statin (simvastatin 20 mg, orally, once per day). The discordant BMI results may be due to different dosages of metformin (850 mg twice per day in <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> and 1000 mg once per day in <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a>). A higher dose of metformin may help to lower BMI. </p> <p>The studies that recorded adverse effects reported either that no significant adverse effects occurred, or that there were no differences between the intervention and control groups. All studies had a short duration (six weeks to six months); long‐term data on the comparative effects of statins are lacking. </p> </section> <section id="CD008565-sec-0186"> <h3 class="title" id="CD008565-sec-0186">Overall completeness and applicability of evidence</h3> <p>Overall, all studies clearly defined their populations and the diagnostic criteria of PCOS, but the diagnostic criteria differed across studies. In addition, there were significant baseline differences between study groups; for example, in <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>, the women treated with statins had higher fasting insulin, testosterone, and free androgen index. </p> <p>Owing to the limited number of eligible studies, we were unable to perform sensitivity analyses to check the effect of the differences in diagnostic criteria. Furthermore, there were differences in BMI and serum insulin levels between the included studies at baseline. In <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a>, the participants had a normal BMI, and more than 50% of women in the OCP group had a serum testosterone level below 80 ng/dL and an insulin level below 15 µIU/L, whereas <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> and <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> included obese women with high insulin levels. Data in this review are derived from women with PCOS who were recruited from sites in Europe, the USA, and Iran. This may limit the applicability of our results, if ethnic variation affects the risk of clinical or metabolic adverse outcomes or responses to statin therapy. </p> <p>There are a limited number of RCTs evaluating statins versus placebo or statins combined with another drug versus the other drug alone. Another factor that may limit the applicability of this review is the small sample sizes, which translated to imprecise results and low confidence in the conclusions. We were unable to perform some planned analyses owing to the limited number of studies. </p> <p>The included studies only partially addressed the objectives of this review in terms of reporting of outcomes. Only two studies reported our primary outcome resumption of menstrual regularity, and no studies reported resumption of ovulation, which was our second primary outcome. </p> <p>Three studies measured serum testosterone as a primary outcome. Because the evidence was of very low certainty, we could not confirm if statins were effective in reducing testosterone levels. There are insufficient studies to date assessing whether a favourable biochemical androgen profile leads to improvement in the symptoms of hirsutism and acne. In addition, the number of readings and timing for serum testosterone measurement affect the internal validity of the study result, so primary studies should describe measurement methods in detail. Some studies in this review took only a single reading at baseline and the endpoint. There were no serious adverse events reported, but the studies provided no data to confirm the safety profile of statins in women with PCOS in the long term. While statins were previously considered teratogenic, more recent evidence has refuted these concerns surrounding statins in pregnancy (<a href="./references#CD008565-bbs2-0066" title="KaralisDG , HillAN , CliftonS , WildRA . The risks of statin use in pregnancy: a systematic review. Journal of Clinical Lipidology2016;10(5):1081-90.">Karalis 2016</a>; <a href="./references#CD008565-bbs2-0069" title="Ma'ayehM , RoodKM , KnissD , CostantineMM . Novel interventions for the prevention of preeclampsia. Current Hypertension Reports2020;22(2):17.">Ma'ayeh 2020</a>). </p> <p>No studies mentioned the time of administration of statins, though this factor influences their efficacy: there are sufficient data to support evening administration of simvastatin, as a short‐acting statin, for achieving optimal lowering of LDL cholesterol (<a href="./references#CD008565-bbs2-0038" title="AwadK , BanachM . The optimal time of day for statin administration: a review of current evidence. Current Opinion in Lipidology2018;29(4):340-5.">Awad 2018</a>). </p> </section> <section id="CD008565-sec-0187"> <h3 class="title" id="CD008565-sec-0187">Quality of the evidence</h3> <p>For details see <a href="./full#CD008565-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD008565-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD008565-tbl-0003">summary of findings Table 3</a>, <a href="./full#CD008565-tbl-0004">summary of findings Table 4</a>, and <a href="./full#CD008565-tbl-0005">summary of findings Table 5</a>. The certainty of the evidence for all main outcomes was very low. </p> <p>All studies were at high risk of bias in at least one domain. <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> and <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not clearly describe the methods used for random sequence generation or allocation concealment. <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> and <a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> were at high risk of performance and detection bias, and all studies except <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> were at high risk of reporting bias. We downgraded the certainty of the evidence for all outcomes for serious or very serious risk of bias concerns. </p> <p>Another reason for downgrading the certainty of the evidence was serious or very serious imprecision. All results were constrained by small numbers of participants, which led to wide CIs (indicating limited precision). Meta‐analysis was not possible for most primary and secondary outcomes because no trials or only a single trial provided analysable data. There is a need for well‐designed RCTs with large sample sizes to confirm or refute the current evidence. </p> </section> <section id="CD008565-sec-0188"> <h3 class="title" id="CD008565-sec-0188">Potential biases in the review process</h3> <p>To limit bias in the review process, the CGF Group guided and developed the search, applying no restrictions on language of publication. Two review authors independently performed study selection, risk of bias assessment, and data collection, resolving any disagreements by discussion with a third review author. When contact details were available, we contacted authors of potentially eligible trials for more information. We have listed some studies as awaiting classification pending confirmation of study data by study authors. </p> </section> <section id="CD008565-sec-0189"> <h3 class="title" id="CD008565-sec-0189">Agreements and disagreements with other studies or reviews</h3> <p>Since the publication of the previous version of this review in 2011 (<a href="./references#CD008565-bbs2-0094" title="RavalAD , HunterT , StuckeyB , HartRJ . Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database of Systematic Reviews2011, Issue 10. Art. No: CD008565. [DOI: 10.1002/14651858.CD008565.pub2]">Raval 2011</a>), five systematic reviews have examined the effect of statins on clinical and biochemical parameters in women with PCOS (<a href="./references#CD008565-bbs2-0033" title="AbdallaMA , ShahN , DeshmukhH , SahebkarA , ÖstlundhL , Al-Rifai RamiH , et al. Effect of pharmacological interventions on lipid profiles and C-reactive protein in polycystic ovary syndrome: a systematic review and meta-analysis. Clinical Endocrinology (Oxford)2022;96(4):443-59.">Abdalla 2022</a>; <a href="./references#CD008565-bbs2-0043" title="ChenJ , HuangC , ZhangT , GongW , DengX , LiuH , et al. The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology2021;19(1):189.">Chen 2021a</a>; <a href="./references#CD008565-bbs2-0044" title="ChenLL , ZhengJH . Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome: A systematic review and meta-analysis. Medicine (Baltimore)2021;100(24):e26289.">Chen 2021b</a>; <a href="./references#CD008565-bbs2-0068" title="LiuY , ShaoY , XieJ , ChenL , ZhuG . The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: A meta-analysis and systematic review. Medicine (Baltimore)2021;100(31):e26622.">Liu 2021</a>; <a href="./references#CD008565-bbs2-0070" title="MiaoK , ZhouH . Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta-analysis. Journal of Obstetrics and Gynaecology Research2022;48(7):1806-15.">Miao 2022</a>). </p> <p><a href="./references#CD008565-bbs2-0033" title="AbdallaMA , ShahN , DeshmukhH , SahebkarA , ÖstlundhL , Al-Rifai RamiH , et al. Effect of pharmacological interventions on lipid profiles and C-reactive protein in polycystic ovary syndrome: a systematic review and meta-analysis. Clinical Endocrinology (Oxford)2022;96(4):443-59.">Abdalla 2022</a> included three studies, one of which was excluded from our review (not truly randomised), to analyse the effect of atorvastatin on lipid profiles and CRP in PCOS. <a href="./references#CD008565-bbs2-0033" title="AbdallaMA , ShahN , DeshmukhH , SahebkarA , ÖstlundhL , Al-Rifai RamiH , et al. Effect of pharmacological interventions on lipid profiles and C-reactive protein in polycystic ovary syndrome: a systematic review and meta-analysis. Clinical Endocrinology (Oxford)2022;96(4):443-59.">Abdalla 2022</a> and our review reached similar conclusions regarding the effect of statins on lipid profiles and CRP. </p> <p><a href="./references#CD008565-bbs2-0043" title="ChenJ , HuangC , ZhangT , GongW , DengX , LiuH , et al. The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology2021;19(1):189.">Chen 2021a</a> focussed on the effect of statins on hyperandrogenism in women with PCOS; it included nine studies, five of which were also included in our review. The remaining four studies were either excluded from our review (not truly randomised) or listed as awaiting classification due to data integrity concerns. As a result, there are some inconsistencies between our results and those of <a href="./references#CD008565-bbs2-0043" title="ChenJ , HuangC , ZhangT , GongW , DengX , LiuH , et al. The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology2021;19(1):189.">Chen 2021a</a>. </p> <p><a href="./references#CD008565-bbs2-0044" title="ChenLL , ZhengJH . Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome: A systematic review and meta-analysis. Medicine (Baltimore)2021;100(24):e26289.">Chen 2021b</a> included nine studies and analysed the effects of atorvastatin on insulin resistance in women with PCOS. The women in the atorvastatin group had lower fasting insulin levels than those in the placebo group, whereas we found no significant differences between the statin and placebo groups. However, <a href="./references#CD008565-bbs2-0044" title="ChenLL , ZhengJH . Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome: A systematic review and meta-analysis. Medicine (Baltimore)2021;100(24):e26289.">Chen 2021b</a> reported decreased HOMA‐IR with atorvastatin therapy, as in our review. </p> <p><a href="./references#CD008565-bbs2-0068" title="LiuY , ShaoY , XieJ , ChenL , ZhuG . The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: A meta-analysis and systematic review. Medicine (Baltimore)2021;100(31):e26622.">Liu 2021</a> studied the efficacy and safety of metformin combined with simvastatin for the treatment of PCOS. It included two RCTs published by the same author group (one of which was <a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a>). <a href="./references#CD008565-bbs2-0068" title="LiuY , ShaoY , XieJ , ChenL , ZhuG . The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: A meta-analysis and systematic review. Medicine (Baltimore)2021;100(31):e26622.">Liu 2021</a> included results from different durations (three months and six months) of the same clinical trial, so there is a possibility of duplicate data. We included data reported after six months of treatment only. </p> <p><a href="./references#CD008565-bbs2-0070" title="MiaoK , ZhouH . Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta-analysis. Journal of Obstetrics and Gynaecology Research2022;48(7):1806-15.">Miao 2022</a> included 13 studies to analyse the effect of statins (alone or in combination with metformin) on PCOS, and did not group publications from the same trials. The results showed a significant decline in total testosterone with statins, whereas our meta‐analyses produced uncertain results for this outcome. <a href="./references#CD008565-bbs2-0070" title="MiaoK , ZhouH . Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta-analysis. Journal of Obstetrics and Gynaecology Research2022;48(7):1806-15.">Miao 2022</a> also demonstrated a significant improvement in lipid profile, glucose metabolism, and hs‐CRP, which was consistent with our results. </p> <p>There is a 2021 Cochrane Review investigating the effects of statins on testosterone levels in male and female populations, including women with PCOS (<a href="./references#CD008565-bbs2-0086" title="ShawishMI , BagheriB , MusiniVM , AdamsSP , WrightJM . Effect of atorvastatin on testosterone levels. Cochrane Database of Systematic Reviews2021;1(1):CD013211.">Shawish 2021</a>); that review included three of the studies included in our review (<a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>; <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a>; <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). <a href="./references#CD008565-bbs2-0086" title="ShawishMI , BagheriB , MusiniVM , AdamsSP , WrightJM . Effect of atorvastatin on testosterone levels. Cochrane Database of Systematic Reviews2021;1(1):CD013211.">Shawish 2021</a> concluded that atorvastatin compared with placebo decreased total testosterone levels in women with PCOS, whereas we found no evidence of a difference in testosterone levels between statin and placebo (very low‐certainty evidence). The difference in results is due to the fact that <a href="./references#CD008565-bbs2-0086" title="ShawishMI , BagheriB , MusiniVM , AdamsSP , WrightJM . Effect of atorvastatin on testosterone levels. Cochrane Database of Systematic Reviews2021;1(1):CD013211.">Shawish 2021</a> pooled all studies regardless of duration of treatment in one analysis. When we analysed the results per subgroup based on duration of treatment, we saw no such effect of statin on testosterone levels; only one study showed a reduction (<a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>). In addition, the analyses in <a href="./references#CD008565-bbs2-0086" title="ShawishMI , BagheriB , MusiniVM , AdamsSP , WrightJM . Effect of atorvastatin on testosterone levels. Cochrane Database of Systematic Reviews2021;1(1):CD013211.">Shawish 2021</a> comparing the effect of statins versus placebo on testosterone levels also included data from <a href="./references#CD008565-bbs2-0007" title="AkbariM , AlmasiA , NaderiZ , KouhpayezadehJ , PouraliR , HossinzadehZ . The effect of atorvastatin on the ovarian arterial blood flow and serum androgen level in PCOS patient. Biomedical and Pharmacology Journal2016;9(3):1041-8. ">Akbari 2016</a>, which we excluded because it used a sequential non‐random sampling method. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008565-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD008565-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008565-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008565-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 1: Resumption of menstrual regularity (menstrual cycle length in days)" data-id="CD008565-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 1: Resumption of menstrual regularity (menstrual cycle length in days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 2: Body mass index (kg/m2)" data-id="CD008565-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 2: Body mass index (kg/m<sup>2</sup>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 3: Waist circumference (cm)" data-id="CD008565-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 3: Waist circumference (cm)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 4: Waist‐hip ratio" data-id="CD008565-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 4: Waist‐hip ratio</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 5: Improvement in testosterone level (nmol/L)" data-id="CD008565-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 5: Improvement in testosterone level (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 6: Total cholesterol (mmol/L)" data-id="CD008565-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 6: Total cholesterol (mmol/L)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 7: Low‐density lipoprotein (LDL) cholesterol (mmol/L)" data-id="CD008565-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 7: Low‐density lipoprotein (LDL) cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 8: High‐density lipoprotein (HDL) cholesterol (mmol/L)" data-id="CD008565-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 8: High‐density lipoprotein (HDL) cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 9: Triglycerides (mmol/L)" data-id="CD008565-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 9: Triglycerides (mmol/L)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 10: Improvement in high‐sensitivity C‐reactive protein (nmol/L)" data-id="CD008565-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 10: Improvement in high‐sensitivity C‐reactive protein (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 11: Fasting insulin (μIU/L)" data-id="CD008565-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 11: Fasting insulin (μIU/L)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 12: Homeostatic model assessment for insulin resistance" data-id="CD008565-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 12: Homeostatic model assessment for insulin resistance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Statin versus placebo, Outcome 13: Intravenous glucose tolerance test (IVGTT) insulin sensitivity" data-id="CD008565-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Statin versus placebo, Outcome 13: Intravenous glucose tolerance test (IVGTT) insulin sensitivity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Statin plus metformin versus metformin alone, Outcome 1: Resumption of menstrual regularity (spontaneous menses per 6 months)" data-id="CD008565-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Statin plus metformin versus metformin alone, Outcome 1: Resumption of menstrual regularity (spontaneous menses per 6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Statin plus metformin versus metformin alone, Outcome 2: Body mass index (kg/m2)" data-id="CD008565-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Statin plus metformin versus metformin alone, Outcome 2: Body mass index (kg/m<sup>2</sup>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Statin plus metformin versus metformin alone, Outcome 3: Improvement in hirsutism (Ferriman‐Gallwey score)" data-id="CD008565-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Statin plus metformin versus metformin alone, Outcome 3: Improvement in hirsutism (Ferriman‐Gallwey score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Statin plus metformin versus metformin alone, Outcome 4: Improvement in acne severity (score)" data-id="CD008565-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Statin plus metformin versus metformin alone, Outcome 4: Improvement in acne severity (score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Statin plus metformin versus metformin alone, Outcome 5: Improvement in testosterone level (nmol/L)" data-id="CD008565-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Statin plus metformin versus metformin alone, Outcome 5: Improvement in testosterone level (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Statin plus metformin versus metformin alone, Outcome 6: Total cholesterol (mmol/L)" data-id="CD008565-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Statin plus metformin versus metformin alone, Outcome 6: Total cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Statin plus metformin versus metformin alone, Outcome 7: Low‐density lipoprotein (LDL) cholesterol (mmol/L)" data-id="CD008565-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Statin plus metformin versus metformin alone, Outcome 7: Low‐density lipoprotein (LDL) cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Statin plus metformin versus metformin alone, Outcome 8: High‐density lipoprotein (HDL) cholesterol (mmol/L)" data-id="CD008565-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Statin plus metformin versus metformin alone, Outcome 8: High‐density lipoprotein (HDL) cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Statin plus metformin versus metformin alone, Outcome 9: Triglyceride levels (mmol/L)" data-id="CD008565-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Statin plus metformin versus metformin alone, Outcome 9: Triglyceride levels (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Statin plus metformin versus metformin alone, Outcome 10: Fasting insulin (μIU/L)" data-id="CD008565-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Statin plus metformin versus metformin alone, Outcome 10: Fasting insulin (μIU/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 1: Body mass index (kg/m2)" data-id="CD008565-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 1: Body mass index (kg/m<sup>2</sup>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 2: Improvement in hirsutism (Ferriman‐Gallwey score)" data-id="CD008565-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 2: Improvement in hirsutism (Ferriman‐Gallwey score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 3: Improvement in testosterone level (nmol/L)" data-id="CD008565-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 3: Improvement in testosterone level (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 4: Total cholesterol (mmol/L)" data-id="CD008565-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 4: Total cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 5: Low‐density lipoprotein (LDL) cholesterol (mmol/L)" data-id="CD008565-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 5: Low‐density lipoprotein (LDL) cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 6: High‐density lipoprotein (HDL) cholesterol (mmol/L)" data-id="CD008565-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 6: High‐density lipoprotein (HDL) cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 7: Triglyceride levels (mmol/L)" data-id="CD008565-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 7: Triglyceride levels (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 8: Fasting insulin (μIU/L)" data-id="CD008565-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 8: Fasting insulin (μIU/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 9: Homeostatic model assessment (HOMA) for insulin resistance" data-id="CD008565-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Statin plus oral contraceptive pill (OCP) versus OCP alone, Outcome 9: Homeostatic model assessment (HOMA) for insulin resistance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 1: Resumption of menstrual regularity (spontaneous menses per 6 months)" data-id="CD008565-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 1: Resumption of menstrual regularity (spontaneous menses per 6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 2: Body mass index (kg/m2)" data-id="CD008565-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 2: Body mass index (kg/m<sup>2</sup>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 3: Waist circumference (cm)" data-id="CD008565-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 3: Waist circumference (cm)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 4: Improvement in hirsutism (Ferriman‐Gallwey score)" data-id="CD008565-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 4: Improvement in hirsutism (Ferriman‐Gallwey score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 5: Improvement in acne severity (score)" data-id="CD008565-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 5: Improvement in acne severity (score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 6: Improvement in testosterone level (nmol/L)" data-id="CD008565-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 6: Improvement in testosterone level (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 7: Total cholesterol (mmol/L)" data-id="CD008565-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 7: Total cholesterol (mmol/L)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 8: Low‐density lipoprotein (LDL) cholesterol (mmol/L)" data-id="CD008565-fig-0043" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 8: Low‐density lipoprotein (LDL) cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 9: High‐density lipoprotein (HDL) cholesterol (mmol/L)" data-id="CD008565-fig-0044" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 9: High‐density lipoprotein (HDL) cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 10: Triglyceride levels (mmol/L)" data-id="CD008565-fig-0045" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 10: Triglyceride levels (mmol/L)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 11: High‐sensitivity C‐reactive protein (nmol/L)" data-id="CD008565-fig-0046" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 11: High‐sensitivity C‐reactive protein (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Statin versus metformin, Outcome 12: Fasting insulin (μIU/L)" data-id="CD008565-fig-0047" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: Statin versus metformin, Outcome 12: Fasting insulin (μIU/L)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Statin versus oral contraceptive pill (OCP) plus flutamide, Outcome 1: Body mass index (kg/m2)" data-id="CD008565-fig-0048" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Statin versus oral contraceptive pill (OCP) plus flutamide, Outcome 1: Body mass index (kg/m<sup>2</sup>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Statin versus oral contraceptive pill (OCP) plus flutamide, Outcome 2: Waist circumference (cm)" data-id="CD008565-fig-0049" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Statin versus oral contraceptive pill (OCP) plus flutamide, Outcome 2: Waist circumference (cm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Statin versus oral contraceptive pill (OCP) plus flutamide, Outcome 3: High‐density lipoprotein (HDL) cholesterol (mmol/L)" data-id="CD008565-fig-0050" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Statin versus oral contraceptive pill (OCP) plus flutamide, Outcome 3: High‐density lipoprotein (HDL) cholesterol (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Statin versus oral contraceptive pill (OCP) plus flutamide, Outcome 4: Triglycerides (mmol/L)" data-id="CD008565-fig-0051" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Statin versus oral contraceptive pill (OCP) plus flutamide, Outcome 4: Triglycerides (mmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008565-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/urn:x-wiley:14651858:media:CD008565:CD008565-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Statin versus oral contraceptive pill (OCP) plus flutamide, Outcome 5: High‐sensitivity C‐reactive protein (nmol/L)" data-id="CD008565-fig-0052" src="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_t/tCD008565-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Statin versus oral contraceptive pill (OCP) plus flutamide, Outcome 5: High‐sensitivity C‐reactive protein (nmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/media/CDSR/CD008565/image_n/nCD008565-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008565-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Statin compared to placebo for women with polycystic ovary syndrome not actively trying to conceive</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Statin compared to placebo for women with polycystic ovary syndrome not actively trying to conceive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome not actively trying to conceive<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> statin<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with statin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Resumption of menstrual regularity</b> (menstrual cycle length in days) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual cycle length was 52 days.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2 days fewer<br/>(24.86 fewer to 20.86 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Resumption of spontaneous ovulation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No studies reported spontaneous ovulation.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Improvement in hirsutism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No studies reported hirsutism.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Improvement in acne severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>No studies reported acne severity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Improvement in testosterone level</b> (nmol/L) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 6 weeks' treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level after 6 weeks' treatment was −0.58 nmol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 nmol/L higher<br/>(0.72 lower to 0.84 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 3 months' treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level (nmol/L) after 3 months' treatment was −0.1 nmol/L. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.53 nmol/L lower<br/>(1.61 lower to 0.54 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 6 months' treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level (nmol/L) after 6 months' treatment was −0.2 nmol/L. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.10 nmol/L higher<br/>(0.43 lower to 0.63 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>2 studies assessed adverse events and neither reported a significant difference between the groups.<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision (wide CI, small sample size) and once for risk of bias.<br/><sup>b</sup> One woman in the statin group stopped the treatment for arthralgia in <a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a>. No adverse events were observed in either group in <a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a>. <a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> did not report adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Statin compared to placebo for women with polycystic ovary syndrome not actively trying to conceive</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008565-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Statin plus metformin compared to metformin alone for women with polycystic ovary syndrome not actively trying to conceive</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Statin plus metformin compared to metformin alone for women with polycystic ovary syndrome not actively trying to conceive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome not actively trying to conceive<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> statin + metformin<br/><b>Comparison:</b> metformin alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with metformin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with statin + metformin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resumption of menstrual regularity</b> (spontaneous menses per 6 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of spontaneous menses per 6 months was 1.1.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.6 menses more<br/>(0.08 fewer to 1.12 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resumption of spontaneous ovulation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> did not report spontaneous ovulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in hirsutism</b> (Ferriman‐Gallwey score) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in hirsutism after 6 months' treatment was −0.84.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.16 lower<br/>(0.91 lower to 0.59 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in acne severity</b> (scale of 0–3) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in acne severity after 6 months' treatment was −0.75.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.31 lower<br/>(0.67 lower to 0.05 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in testosterone level</b> (nmol/L) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level after 6 months' treatment was −0.52 nmol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 nmol/L lower<br/>(0.37 lower to 0.31 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported that no significant adverse events had occurred. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision (wide CI, small sample size, single study) and twice for very serious risk of bias concerns. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Statin plus metformin compared to metformin alone for women with polycystic ovary syndrome not actively trying to conceive</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008565-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Statin plus oral contraceptive pill compared to oral contraceptive pill alone for women with polycystic ovary syndrome not actively trying to conceive</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Statin plus OCP compared to OCP for women with polycystic ovary syndrome not actively trying to conceive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome not actively trying to conceive<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> statin + OCP<br/><b>Comparison:</b> OCP </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with OCP</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with statin + OCP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resumption of menstrual regularity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report resumption of menstrual regularity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resumption of spontaneous ovulation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report on resumption of spontaneous ovulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in hirsutism</b> (Ferriman‐Gallwey score) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in hirsutism was −0.13.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.12 lower<br/>(0.41 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in acne severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> did not report acne severity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Testosterone level</b> (change from baseline in nmol/L) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level (nmol/L) was −0.38 nmol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.82 nmol/L lower<br/>(1.38 lower to 0.26 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> reported that no significant adverse events occurred. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>*The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OCP:</b> oral contraceptive pill. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision (wide CI, small sample size, single study) and twice for very serious risk of bias concerns. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Statin plus oral contraceptive pill compared to oral contraceptive pill alone for women with polycystic ovary syndrome not actively trying to conceive</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008565-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Statin compared to metformin for women with polycystic ovary syndrome not actively trying to conceive</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Statin compared to metformin for women with polycystic ovary syndrome not actively trying to conceive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome not actively trying to conceive<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> statin<br/><b>Comparison:</b> metformin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with metformin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with statin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resumption of menstrual regularity</b> (number of spontaneous menses per 6 months) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of spontaneous menses per 6 months after 6 months' treatment was 1.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.5 menses more<br/>(0.05 more to 1.05 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resumption of spontaneous ovulation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No studies reported resumption of spontaneous ovulation.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in hirsutism</b> (Ferriman‐Gallwey score) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in hirsutism after 6 months' treatment was −0.84.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.26 lower<br/>(0.97 lower to 0.45 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in acne severity</b> (scale of 0–3) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in acne score after 6 months' treatment was −0.75.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.18 lower<br/>(0.53 lower to 0.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in testosterone level</b> (nmol/L) after 6 months' treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in testosterone level after 6 months' treatment was −0.52 nmol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.24 nmol/L lower<br/>(0.58 lower to 0.1 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>The studies reported that no significant adverse events had occurred.<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> Downgraded twice for very serious imprecision (wide CI, small sample size, single study) and twice for very serious risk of bias concerns.<br/><sup>b</sup><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> reported that six subjects using metformin experienced transient gastrointestinal side effects including diarrhoea; however, these side effects did not result in discontinuation of treatment. <a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> reported that no participants experienced significant side effects. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Statin compared to metformin for women with polycystic ovary syndrome not actively trying to conceive</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008565-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Statin compared to oral contraceptive pill plus flutamide for women with polycystic ovary syndrome not actively trying to conceive</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Statin compared to OCP plus flutamide for women with polycystic ovary syndrome not actively trying to conceive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome not actively trying to conceive<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> statin<br/><b>Comparison:</b> OCP plus flutamide </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with OCP alone or in combination with another agent</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with statin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resumption of menstrual regularity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report resumption of menstrual regularity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resumption of spontaneous ovulation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report resumption of spontaneous ovulation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in hirsutism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report hirsutism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in acne severity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report acne severity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in testosterone level.</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> did not report testosterone levels. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> reported that no women experienced any significant side effects. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OCP:</b> oral contraceptive pill. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Statin compared to oral contraceptive pill plus flutamide for women with polycystic ovary syndrome not actively trying to conceive</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008565-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Conversion factors</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Convert from</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Convert to</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conversion factor</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholesterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.026</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>μIU/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1667</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.056</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Testosterone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03467</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High‐sensitivity C‐reactive protein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.524</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sqrt n</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(upper limit−lower limit)/3.92</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Conversion factors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008565-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study group (n)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline demographics, mean (SD)</b> </p> </th> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline biochemistry, mean (SD)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BMI (kg/m<sup>2</sup>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total T (nmol/L)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>FI <b>(µIU/ml)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TC (mmol/L)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>HDL (mmol/L)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LDL (mmol/L)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TG (mmol/L)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sim + met (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.3 (4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.8 (5.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.95 (0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.10 (5.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.79 (0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.68 (0.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.64 (0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: sim (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.3 (4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.5 (4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.91 (0.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.90 (4.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.96 (0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.79 (0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.80 (0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: met (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0 (4.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.7 (4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.91 (0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.10 (4.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.53 (0.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.57 (0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.51 (0.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.51)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sim + OCP (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.0 (3.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.7 (2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.96 (0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (3.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.02 (0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.69 (0.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.78 (0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: OCP (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.8 (3.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8 (3.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.62 (0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 (4.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.86 (1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.59 (0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.76 (0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.08 (0.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sim (34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2 (8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.9 (4.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.21 (0.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: OCP + flu (34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.0 (7.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.8 (4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: met (34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2 (8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.8 (4.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.20 (0.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: AT (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.5 (5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.4 (8.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.30 (10.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.20 (0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.52 (0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.30 (0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (0.50)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: P (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5 (4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7 (4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.10 (3.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.90 (0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.50 (0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.00 (1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: AT (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.8 (4.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.1 (11.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.13 (0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6 (10.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.58 (1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.15 (0.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.64 (0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.73 (0.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: P (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.4 (5.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.0 (10.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.20 (1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8 (9.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.24 (0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20 (0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.40 (0.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.41 (0.60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: AT (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6 (5.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.2 (6.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.10 (0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.6 (7.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.60 (0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.90 (0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34 (0.35)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: P (18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8 (7.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.9 (5.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.40 (0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4 (8.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.50 (0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.70 (0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.39 (1.02)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>a. 86% of participants had irregular menstrual cycle (≤ 8 spontaneous cycles/year), 79% had hirsutism, and 82% had acne.<br/>b. 73% of participants had irregular menstrual cycle.<br/>AT: atorvastatin; BMI: body mass index; C: control; I: intervention; FI: fasting insulin; flu: flutamide; HDL: high‐density lipoprotein cholesterol; LDL: low‐density lipoprotein cholesterol; met: metformin; NR: not reported; sim: simvastatin; SD: standard deviation; T: testosterone; TC: total cholesterol; TG: total glucose. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008565-tbl-0008"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Attrition table</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Screened, n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Treatment groups</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomised, n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Completed, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reasons for attrition</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD008565-bbs2-0001" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88 Suppl 1:74, Abstract no: 196. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism2009;94(12):4938-45. BanaszewskaB , PawelczykL , SpaczynskiRZ , DulebaAJ . Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. Journal of Clinical Endocrinology and Metabolism2011;96(11):3493-501. [PMID: 21865358]BanaszewskaaB , PawelczykaL , SpaczynskiaR , DulebaAJ . Comparison of effects of simvastatin and metformin in women with PCOS: a randomized trial. Fertility and Sterility2007;88:574. DulebaA , BanaszewskaB , SpaczynskiRZ , Diamanti-KandarakisE , PawelczykL . Metformin, but not simvastatin, reduces serum levels of advanced glycation end products in women with PCOS: results of a randomized trial. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual meeting Amsterdam 28 June to 1 July2009;24 Suppl 1:i181 P-453 Poster. KarakasSE , BanaszewskaB , SpaczynskiRZ , PawelczykL , DulebaA . Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecological Endocrinology2013;29(5):483-7. [PMID: 23480783]PawelczykL , BanaszewskaB , SpaczynskiRZ , DulebaAJ . Randomized trial comparing simvastatin and metformin in women with PCOS: outcomes at six months. Fertility and Sterility2008;92(3):S31-2. ">Banaszewska 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: simvastatin + metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months: 37 (84%)</p> <p>6 months: 36 (82%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Loss of contact due to changes in telephone, mail, or residence address; or immigration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: simvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months: 41 (85%)</p> <p>6 months: 28 (58%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months: 36 (77%)</p> <p>6 months: 33 (70%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months: 114 (82%)</p> <p>6 months: 97 (70%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0002" title="BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism2007;92(2):456-61. BanaszewskaB , PawelczykL , SpaczynskiRZ , DziuraJ , DulebaAJ . Simvastatin improves hyperandrogenism, hyperandrogenemia, LH and lipid profile in women with PCOS: a randomized, cross-over study. Fertility and Sterility2005;84 Suppl 1:54-5. DulebaAJ , BanaszewskaB , SpaczynskiRZ , DziuraJ , PawelczykL . Simvastatin reduces systemic inflammation and improves endothelial function in women with PCOS; randomized crossover study. Human Reproduction2006;21:i87. DulebaAJ , BanaszewskaB , SpaczynskiRZ , PawelczykL . Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility2006;85(4):996-1001. ">Duleba 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: simvastatin + OCP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: OCP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (100%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD008565-bbs2-0003" title="MehrabianF , Ghasemi-TehraniH , MohamadkhaniM , MoeinoddiniM , KarimzadehP . Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences: Official Journal of Isfahan University of Medical Sciences2016;21:7. [PMID: 27904553]">Mehrabian 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: simvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (92%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Loss to follow‐up, non‐compliance with study protocol, refusal to continue participating in study, not using allocated treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: flutamide + OCP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C2: metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 (92%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0004" title="HukkanenJ , PuurunenJ , HyotylainenT , SavolainenMJ , RuokonenA , Morin-PapunenL , et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. British Journal of Clinical Pharmacology2015;80(3):473-9. [PMID: 26095142]LuotolaK , PiltonenTT , PuurunenJ , Morin-PapunenLC , TapanainenJS . Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecological Endocrinology: Official Journal of The International Society of Gynecological Endocrinology2018;34(1):40-4. [PMID: 28678568]PuurunenJ , PiltonenT , PukkaK , RuokonenA , SavolainenMJ , BloiguR , et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2013;98:4798-807. [Clinicaltrial.gov: NCT01072097] [EU Clinical Trials Register (identifier code 2006-003584-31]PuurunenJ , PiltonenT , RuokonenA , SavolainenMJ , Morin-PapunenL , TapanainenJS . Statin therapy impairs insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blinded, placebo-controlled study. Fertility and Sterility2012;98 Suppl 1(3):S2 Abstract no:O-6. ">Puurunen 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: atorvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T2DM (n = 1), non‐adherence (n = 2), arthralgia (n = 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menorrhagia with anaemia (n = 1), T2DM (n = 2), non‐adherence (n = 2), myalgia (n = 1) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0005" title="Raja-KhanN , KunselmanAR , HogemanCS , StetterCM , DemersLM , LegroRS . Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2011;95(5):1849-52. ">Raja‐Khan 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: atorvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Use of OCP during follow‐up period</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (90%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD008565-bbs2-0006" title="SathyapalanT , AtkinSL , KilpatrickES , CoadyAM , ShepherdJ , HobkirkJP , et al. The effect of atorvastatin on adipose tissue inflammation and dysfunction in women with polycystic ovary syndrome. Endocrine Reviews2013;1:no pagination. SathyapalanT , CoadyAM , KilpatrickES , AtkinSL . The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocrine Connections2017;6(8):811-6. [PMID: 29018156]SathyapalanT , HobkirkJP , JavedZ , CarrollS , CoadyAM , PembertonP , et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Frontiers in Endocrinology2019;10:394. [PMID: 31293514]SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology2010;72(4):566-8. SathyapalanT , KilpatrickES , Coady A-M, AtkinSL . The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2009;94(1):103-8. SathyapalanT , ShepherdJ , ArnettC , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry2010;56(11):1696-700. SathyapalanT , ShepherdJ , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology &amp; Metabolism2012;97:3951-5. SathyapalanT , SmithKA , CoadyAM , KilpatrickES , AtkinSL . Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry2012;49(Pt 1):80-5. ">Sathyapalan 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>40/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: atorvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Non‐compliance with statins regimen based on pill count</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (90%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37(93%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1295 (96.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>C: control; I: intervention; NA: not applicable; NR: not reported; OCP: oral contraceptive pill; T2DM: type 2 diabetes mellitus. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Attrition table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/full#CD008565-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008565-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Statin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Resumption of menstrual regularity (menstrual cycle length in days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [‐1.87, 3.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 After 6 weeks' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [‐6.02, 10.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 After 3 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐4.64, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 After 6 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [‐1.38, 9.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Waist circumference (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Waist‐hip ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Improvement in testosterone level (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 After 6 weeks' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.72, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 After 3 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.61, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 After 6 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.43, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.31 [‐1.64, ‐0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 After 6 weeks' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.56 [‐2.17, ‐0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 After 3 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.75, ‐0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 After 6 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.78, ‐0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Low‐density lipoprotein (LDL) cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐1.38, ‐0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 After 6 weeks' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.29 [‐1.82, ‐0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 After 3 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.34, ‐0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 After 6 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.75, ‐0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 High‐density lipoprotein (HDL) cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.15, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 After 6 weeks' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.22, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 After 3 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.28, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 After 6 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.26, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.60, ‐0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 After 6 weeks' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.91, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 After 3 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐1.20, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 After 6 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.50, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Improvement in high‐sensitivity C‐reactive protein (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.76 [‐20.99, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 After 6 weeks' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.19 [‐69.27, 36.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 After 3 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.91 [‐58.16, 14.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 After 6 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.76 [‐19.52, 10.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Fasting insulin (μIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐5.18, 4.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 After 6 weeks' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [‐2.12, 7.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 After 3 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.20 [‐10.96, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 After 6 months' treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [‐5.30, 8.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Homeostatic model assessment for insulin resistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐2.35, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Intravenous glucose tolerance test (IVGTT) insulin sensitivity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Statin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008565-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Statin plus metformin versus metformin alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Resumption of menstrual regularity (spontaneous menses per 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Improvement in hirsutism (Ferriman‐Gallwey score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Improvement in acne severity (score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Improvement in testosterone level (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Low‐density lipoprotein (LDL) cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 High‐density lipoprotein (HDL) cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Triglyceride levels (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Fasting insulin (μIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Statin plus metformin versus metformin alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008565-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Statin plus oral contraceptive pill (OCP) versus OCP alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Improvement in hirsutism (Ferriman‐Gallwey score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.41, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Improvement in testosterone level (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐1.38, ‐0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Low‐density lipoprotein (LDL) cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 High‐density lipoprotein (HDL) cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Triglyceride levels (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Fasting insulin (μIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Homeostatic model assessment (HOMA) for insulin resistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Statin plus oral contraceptive pill (OCP) versus OCP alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008565-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Statin versus metformin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Resumption of menstrual regularity (spontaneous menses per 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐1.53, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Waist circumference (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Improvement in hirsutism (Ferriman‐Gallwey score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Improvement in acne severity (score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Improvement in testosterone level (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Low‐density lipoprotein (LDL) cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 High‐density lipoprotein (HDL) cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.02, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Triglyceride levels (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.29, ‐0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 High‐sensitivity C‐reactive protein (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐2.60, ‐0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Fasting insulin (μIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Statin versus metformin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008565-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Statin versus oral contraceptive pill (OCP) plus flutamide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Waist circumference (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 High‐density lipoprotein (HDL) cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Triglycerides (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 High‐sensitivity C‐reactive protein (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Statin versus oral contraceptive pill (OCP) plus flutamide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008565.pub3/references#CD008565-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008565.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008565-note-0020">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008565-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008565-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008565-note-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008565-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008565-note-0018">Polski</a> </li> <li class="section-language"> <a class="" href="ro#CD008565-note-0019">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD008565-note-0012">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD008565-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008565-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008565-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008565\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008565\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008565\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008565\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008565\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008565.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008565.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008565.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008565.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008565.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717835424"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008565.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717835427"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008565.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc19f7c6f9377',t:'MTc0MDcxNzgzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 